the printed Meeting Program
Transcription
the printed Meeting Program
MECHANISMS OF EFFICACY IN CANCER IMMUNOTHERAPY 14 CIMT Annual Meeting th PROGRAM GUIDE MAY 10–12, 2016 CIMT - Association for Cancer Immunotherapy meeting.cimt.eu cimt.eu PROGRAM GUIDE 2016 14TH ANNUAL MEETING MAY 10–12, 2016 Rheingoldhalle Congress Center Mainz, Germany CIMT Summary CIMT Summary ANNUAL MEETING 2016 SUMMARY CIMT 2016 PROGRAM ABOUT CIMT OVERVIEW Floor Plan, Program 22–23 Introduction, Who We Are, Program Committee 05–06 INFORMATION PROGRAM SCHEDULE Day 1–3, 25–36 Sponsors & Partners, Websites 09–12 SPEAKERS PLENARY SPEAKERS Biography 13–17 INDUSTRY SATELLITE SYMPOSIA SPEAKERS Biography 19-20 INFORMATION INDUSTRY EXHIBITORS 39-41 POSTER PRESENTATIONS 42-43 IMPRINT 68 2 ABSTRACTS ABSTRACT LIST Therapeutic Vaccination 45–48 Cellular Therapy 49–52 Immunomonitoring 53–54 New Targets & New Leads 55–57 Improving Immunity 58–59 Tumor Biology and Interaction with the Immune System 60–64 CIMT 2016 CIMT 2016 INTRODUCTION MECHANISMS OF EFFICACY IN CANCER IMMUNOTHERAPY DEAR COLLEAGUES, MEMBERS AND FRIENDS EXECUTIVE BOARD: Christoph Huber, Chair Mainz, Germany Peter Johnson Southampton, UK Ulrich Kalinke Hanover, Germany Cornelis Melief Welcome to the 14th Annual Meeting of the Association for Cancer Immunotherapy! Leiden, The Netherlands Hans-Georg Rammensee After a surge of recent approvals and promising research studies, Tübingen, Germany we now see immunotherapies included in the standard of care. Cancer patients are benefiting from immune checkpoint inhibitors, Carl Figdor adoptive cell therapy using engineered T cells is moving through Nijmegen, The Netherlands clinical testing, and highly individualized immunotherapies show the potential to address the complex and ever-changing tumor environments. To optimize clinical benefits for each and every patient, potent combination and individualized therapies promise another Dolores J. Schendel Munich, Germany breakthrough in cancer treatment. As we see therapeutic effects, we now face the challenge of elu- Axel Hoos cidating the mechanisms of efficacy for these therapeutic break Collegeville, USA throughs in order to carefully integrate them into standard treatment protocols. In this year`s meeting, you will hear updates of the state-of-thefield, from regulatory aspects to new targets and drug modalities to Özlem Türeci Mainz, Germany increased understanding of immunotherapeutic efficacy. We have put together an exciting scientific program with outstanding speakers who kindly accepted our invitation to share their knowledge. As always, CIMT will provide you with the opportunity to meet and interact with friends and colleagues in person. Early-career scien- Sebastian Kreiter Mainz, Germany Chairman of CIMT Management Board tists will have the opportunity to present their work in poster and oral presentations. For the first time, a Meet the Editor session will enable direct interaction with the editors of prestigious journals in a panel discussion. A dedicated Voice of the Patients session will reflect the view of our most important partners in the quest for optimized cancer immunotherapies. Thank you for joining us. Yours sincerely, The CIMT Executive Board 4 5 THE ASSOCIATION WHO WE ARE 2016 PROGRAM COMMITTEE: Sebastian Kreiter TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (Mainz, Germany) Sine Reker Hadrup Technical University of Denmark (Copenhagen, Denmark) Sjoerd van der Burg Leiden University Medical Center (Leiden, The Netherlands) Rienk Offringa German Cancer Research Center (DKFZ) (Heidelberg, Germany) The Association for Cancer Immunotherapy (CIMT) was founded in 2002 as an information and education platform for the emerging field of immunological cancer therapy. Physicians and researchers from different fields of clinical Mustafa Diken TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (Mainz, Germany) and theoretical medicine were the founding members of the association. CIMT has since become the leading Euro- Andreas Diefenbach pean communication platform for all aspects of science and Research Center Immunology (FZI) at the Johannes Gutenberg University Mainz (Mainz, Germany) translation in the field of cancer immunotherapy. CIMT operates as an independent non-profit organization in Mainz, Germany, and is financed by donations, sponsoring and Michael Kalos congress fees. Eli Lilly (New York, USA) Our Goals Harpreet Singh CIMT promotes the development of cancer immunothera- Immatics Biotechnologies (Tübingen, Germany) pies by *offering a platform for knowledge exchange between scientists of all faculties interested in cancer immunotherapy. CIMT connects industry-based scientists, academic Ci3 PROJECT: EDUCATION AND NETWORKING PLATFORM FOR INDIVIDUALIZED IMMUNE INTERVENTION CIMT is supported by a research grant from the German Ministry for Education and Research (BMBF) as part of the Rhein-Main Cluster for Individualized Immune Intervention (Ci3). The aim of the project is to advance CIMT as a European education and networking platform for individualized immune intervention medicine that offers the opportunity for information exchange of international top level scientists from academia, industry and regulatory bodies in Mainz and at meetings worldwide. The project will allow to continue and expand the activities of the CIMT Regulatory Research Group and to embark on new activities, such as workshops on technology commercialization (CIMT Endeavour), the co-organization of scientific sessions with international partners (CIMT Satellites) and patient communication (“Voice of the Patients”). The following sessions and workshops during the CIMT 2016 Annual Meeting are supported by the German Ministry for Education and Research (BMBF): TUESDAY, MAY 10 17:30–18:00 Voice of the Patients WEDNESDAY, MAY 11 08:00– 12:00 CIMT Endeavour 08:00– 09:30 Plenary Session 3 on Therapeutic Vaccination 10:00–11:30 Short Talk Session I on Cellular Therapy 14:00–15:30 Plenary Session 4 on Cellular Therapy THURSDAY, MAY 12 08:30– 10:00 Plenary Session 5 on Novel Technologies for Immune Assessment 10:30–11:45 Short Talk Session V on Therapeutic Vaccination 11:45–13:00 Short Talk Session VI on Immunomonitoring 14:30–16:00 Plenary Session 6 on Antibodies scientists, regulatory authorities and physicians alike. *cooperating internationally with partners in related consortia, regulatory agencies, journals, academic institutions and companies. *initiating working groups that actively accelerate the development in the field. *organizing annual meetings, advanced education seminars, symposia, workshops, and by publishing guidelines and textbooks. 6 SUPPORTED BY: CIMT 2016 ANNUAL MEETING SPONSORS & PARTNERS CIMT 2016 is made possible by the generous support from our sponsors and partners: DNA BARCODE DEXTRAMERS ALLOW SCREENING OF 1000+ T CELL SPECIFICITIES IN A SINGLE SAMPLE DNA BARCODE DEXTRAMERS – BIOMARKERS AND TOOL Platinum FOR EPITOPE DISCOVERY FZI ForschungsZentrum Immunologie Gold NEO-EPITOPE DISCOVERY BY MASSIVE MULTIPLEXING The DNA barcoding approach allows hundreds of potential neo-epitopes to be screened in a single cell sample (e.g. blood, TILs), leading to the identification of the few real and biologically relevant neo-epitopes. Silver MULTIPLEXING IN CLINICAL TRIALS The high sensitivity and specificity of the DNA barcoding approach enables a comprehensive analysis of the cellular response to a given treatment, providing valuable information about mechanism-of-action (MoA) and epitope spreading in e.g. adoptive T cell therapy or checkpoint inhibitor treatment. Bronze Get more information about DNA barcode Dextramers on www.immudex.com Sponsors of CIP Partners 9 CIMT 2016 ANNUAL MEETING WEBSITES visit our websites www.cimt.eu & www.meeting.cimt.eu follow us on twitter www.twitter.com/C_IMT #cimt2016 find us on facebook www.facebook.com/cimtmainz follow us on Linkedin www.linkedin.com/company/cimt Smartphone Schedule Get the CIMT online schedule for your smartphone schedule.cimt.eu Online Abstracts Get the CIMT online abstracts (iPad App, eBook, PDF) abstracts.cimt.eu COPYRIGHT AND IMAGE RIGHTS AT CIMT 2016 1.Posters, graphics, lectures are usually protected by international copyright laws. Each lecturer warrants that he holds the rights of use to the items used during his lecture (texts, photographs, graphics). YOU SEE A MOUSE. WE SEE A CURE FOR CANCER. 2.It is not permitted without express prior authorization by the author(s) to take pictures of posters, graphics, people, etc., and to transfer these pictures to third parties via social media (facebook, twitter,….) or webpages. The person taking the pictures must be able to provide proof of such authorization by the author(s) (e.g. author’s mail). Protected material may only be used if the author(s) is mentioned by name. 3.Each participant agrees to indemnify CIMT against any claims for damages by third parties arising from the infringement of any rights by the participant. 4.Each participant agrees to allow CIMT to take pictures of him/her during the event, and he/she agrees to the use of such pictures for CIMT advertising purposes (Internet,…) and press releases. Accelerate your oncology research with the JAX™ NSG mouse – the most immunodeficient strain available. See how the NSG is the obvious choice for your cancer xenograft modelling, immuno-oncology studies, stem cell research and challenging blood tumours. For more information or to enquire about model evaluation, visit us at www.criver.com/nsg. Charles River is the exclusive distributor of JAX™ Mice in Europe. CIMT Speakers ANNUAL MEETING joy we deliver the of health We are working to ensure people remain healthy and vibrant. Visit us at MerckGroup.com PLENARY SPEAKERS Gwendolyn Binder-Scholl Vincenzo Bronte Adaptimmune New York, USA University of Verona Verona, Italy Gwendolyn Binder-Scholl is the founding member and Chief Technology Officer of Adaptimmune, responsible for strategic leadership of platform and pipeline research, and manufacturing sciences. Her original training is in viral neuro-immunology at Johns Hopkins University, Baltimore. Since 2002, she has worked in translational research, cell manufacturing, regulatory affairs, clinical development and translational medicine / correlative research in the field of cell and gene therapy, with a research focus in T-cell immunotherapy for HIV and oncology. She previously held positions at the University of Pennsylvania as the Director of Translational Research Operations, under Carl June, where she oversaw the opening of 5 new INDs for novel gene therapy products. Prior to the University of Pennsylvania, Gwendolyn Binder-Scholl was the Director of Scientific Affairs at Virxsys Corporation, where she was involved in the translational and regulatory aspects of the first human application of a lentiviral vector. Vincenzo Bronte is currently Head of the Immunology Section at the Department of Medicine of Verona University and Head of the U.O.C of Immunology at the Policlinico G. B. Rossi Hospital. He is Full Professor of Immunology at the University of Verona. Vincenzo Bronte’s major achievement has been the definition and characterization of myeloid-derived suppressor cells (MDSCs), whose negative influence on antitumor immunity represents an obstacle to a successful immunotherapy of cancer. Current projects in the laboratory are further exploring the cellular and molecular mechanisms underlying tumor-induced immune dysfunctions, with the attempt to define novel drugs and approaches targeting tumor microenvironment, to be used alone or in combination with either active or passive immunotherapy strategies. Chiara Bonini Rony Dahan Fondazione San Raffaele del Monte Tabor Milan, Italy The Rockefeller University New York, USA Chiara Bonini is Deputy Director of the Research Division of Immunology, Infectious Diseases and Transplantation and Head of the Experimental Hematology Unit at the San Raffaele Scientific Institute in Milan, Italy. Her lab is developing innovative approaches to cancer immunotherapy with genetically modified lymphocytes. She has extensive experience in transplant immunobiology, gene therapy, and cellular therapy. Chiara Bonini is recipient of the Young Investigator Award, American Society of Gene Therapy 2005, the Team Science Recognition Award, International Society for Biological Therapy of Cancer 2010, the Van Bekkum Award, European Society of Bone Marrow Transplantation (EBMT) 2012, and of the Van Rood Award, Immunobiology Working Party EBMT 2013, among others. She is currently chairman of the Cellular Therapy and Immunobiology Working party of EBMT. Rony Dahan is a CRI Irvington postdoctoral fellow in the Laboratory of Molecular Genetics and Immunology at the Rockefeller University. Rony Dahan holds a PhD in molecular immunology from the TechnionIsrael Institute of Technology (2011). He is studying the involvement of Fcγ Receptor pathways in the modes of action of immunomodulatory therapeutic antibodies. His studies include elucidating the contributions of FcγR-engagements for the anti-tumor activity of both antagonistic antibodies targeting the PD-1/PD-L1 axis and agonistic human anti-CD40 antibodies. A recent direction of his research is focused on activity of human IgG-FcγRs interaction using FcγR humanized mouse models. 13 CIMT Speakers 14 CIMT Speakers Giuliano Elia Robert Hawkins Kin-Ming Lo Mikael Pittet Philochem Otelfingen, Switzerland The University of Manchester and The Christie Hospital Manchester, United Kingdom EMD-Serono (Merck KgaA) Billerica, USA Harvard Medical School Cambridge, USA Giuliano Elia obtained his PhD in chemistry at the University of Rome La Sapienza. He worked at CNR's Institute of Experimental Medicine in Rome for a number of years before moving to Switzerland, where he spent time as a visiting scientist at the Friedrich Miescher Institute in Basel. Later, he moved to ETH in Zurich, where he worked in the group of Prof. Dario Neri and as Group Leader of the Proteomic Unit of the Institute of Pharmaceutical Sciences. From 2006 to 2013, Giuliano Elia was Director of the Mass Spectrometry and Proteomics Resource of the Conway Institute, University College Dublin and, from 2009, Coordinator of Post-graduate Education of the same institute. In March 2013, he returned to Switzerland where he took over the position of Senior Director Product Development at Philochem AG. Robert Hawkins is Cancer Research UK Professor of Medical Oncology at the University of Manchester and Christie Hospital. His main clinical interests are in renal/adrenal cancers, focusing on immunotherapy. Robert Hawkins leads a group undertaking translational research into immunotherapy of cancer with a focus on adoptive cell therapy. In addition to pre-clinical research, he has developed a GMP cell therapy unit to provide clinical grade cell manufacturing – this operates as a joint University Facility and a commercial spinout company (Cellular Therapeutics Ltd). He is a founder and CEO of Cellular Therapeutics Ltd that is the first company to produce commercial adoptive cell therapy products for cancer treatment. He is/has been the coordinator of several major European Union consortia in this field. Kin-Ming Lo is Senior Director, Immuno-Oncology Translational Innovation Platform, EMD Serono (Merck KGaA). After holding positions at Abbot Lab and Fuji ImmunoPharmaceuticals (former Lexigen) when it was founded in 1992, he became VP of Research at Lexigen when the company was acquired by EMD in 1999. He remained as VP of Research at EMD Lexigen for ten years, during which he was responsible for the research and development of the immunocytokine and Fc-X technologies. When EMD Serono was formed, he first served as Global Head of Antibody Technologies and later joined the Immuno-Oncology Translational Innovation Platform as Head of Immuno-Technology in late 2012. He is an inventor on over 30 patents and patent applications on antibodies and antibody fusion proteins, including two EMD Serono Immuno-Oncology drug candidates, NHS-IL12 and anti-PD-L1/TGF Trap, currently in clinical trials. Mikael Pittet completed his PhD at the Ludwig Institute for Cancer Research in Lausanne, Switzerland in 2001 and trained as a postdoctoral fellow at Massachusetts General Hospital (MGH), Dana Farber Cancer Institute and Harvard Medical School (HMS) in Boston, USA. Mikael Pittet began his independent research in 2007, currently serves as an Associate Professor at HMS, and is faculty member of the Center for Systems Biology at MGH. His research program focuses on discovering previously unrecognized tumor-host cell interactions and identifying aspects of immune cell dynamics in disease that could establish new paradigms for translational efforts. Work from the Pittet lab combines several approaches, including in-vivo imaging, to study the maturational pathways, trafficking, and functions of immune cell types found in tumors and other diseased tissues. Wolf Hervé Fridman Darrell Irvine Cornelis Melief George Prendergast University Paris-Descartes Paris, Frankreich Massachusetts Institute of Technology Cambridge, USA Leiden University Medical Center and ISA Pharmaceuticals Leiden, The Netherlands Lankenau Institute for Medical Research Wynnewood, USA Wolf H. Fridman is a Professor of Immunology at the Paris Descartes University Medical School in Paris. He founded the Cordeliers Research Centre, a joint research structure between INSERM, University Paris Descartes, and University Pierre et Marie Curie. Wolf Fridman’s research interests have been focused around the role of the immune system in controlling human tumors and the biological functions of Fc receptors. His main contributions in cancer immunology stand up to 1969 when he published, with François Kourilsky, the first demonstration of an immune response of the patient to his own cancer, in acute leukemia. He then focused on the analysis of the tumor microenvironment. His publications with Jérôme Galon and Franck Pagès have changed the paradigm of host/cancer interactions by demonstrating that the “immune contexture” is the major prognostic factor for human cancers. Darrell Irvine is a Professor at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. His research is focused on the application of engineering tools to problems in cellular immunology and the development of new materials for vaccine and drug delivery. Current efforts are focused on problems related to vaccine development for HIV and and immunotherapy of cancer. Darrell Irvine’s work has been recognized by numerous awards, including a Beckman Young Investigator award, an NSF CAREER award, selection for Technology Review’s ‘TR35’, election as a Fellow of the Biomedical Engineering Society, election as a fellow of the American Institute for Medical and Biological Engineering, and appointment as an investigator of the Howard Hughes Medical Institute. He is the author of over 100 publications, reviews, and book chapters and an inventor on numerous patents. Sine Reker Hadrup Cornelis Melief is emeritus professor of internal medicine specialized in “immunohematology” at Leiden University. Since 2011, he has been emeritus professor at LUMC and Chief Scientific Officer of ISA Pharmaceuticals, a biotech company specializing in the development of synthetic vaccines. He received his M.D. and Ph.D. degree from the University of Amsterdam. Cornelis Melief has made many contributions to basic immunology, including work in mouse models, and clinical immunology. In recent years, effective immunotherapy of tumors with synthetic long peptides (SLP) has been developed in mouse and rabbit models. This has led to the implementation of clinical trials in patients with cancer of viral and non-viral origin. Recently, clinical effectiveness was shown in the treatment of patients with established lesions caused by high risk human papilloma virus type 16 (HPV 16). George Prendergast began his career on the faculty of The Wistar Institute in Philadelphia and later directed a drug discovery team at the DuPont Pharmaceuticals Company. In 2002, he moved his groups to the Lankenau Institute for Medical Research to create a unique ‘acapreneurial’ organization that integrates biotech start-up companies with non-profit laboratory and clinical groups to speed translation of discoveries to clinic. From this platform, George Prendergast and his colleagues pioneered the preclinical discovery, validation and clinical translation of indoximod and the first true enzymatic small molecule inhibitors of IDO1. More recently, his team has shown how IDO1 acts to sustain inflammatory processes needed for angiogenesis. This line of work has dovetailed with studies of the IDO2 discovered at Lankenau, which will illustrate critical newly defined roles for this gene in pancreatic cancer and autoimmune disease. Since 2010, George Prendergast has been Editor-in-Chief of Cancer Research. Carl June Paul Parren Ellen Puré Technical University of Denmark Copenhagen, Denmark University of Pennsylvania Philadelphia, USA Genmab Utrecht, The Netherlands University of Pennsylvania Philadelphia, USA Sine Reker Hadrup is an expert in T-cell detection by use of MHC multimers. She has focused for many years on the development of multiplex strategies for T-cell detection to comprehensively assess antigen-specific tumor reactivity among T cells in cancer patients. Sine Reker Hadrup is the head of a research group at the Technical University of Denmark in Herlev. Novel technologies developed in her research group allow the simultaneous detection of more than 1,000 different antigen-responding T cells. Currently, the research group focuses on using this technology to unravel the immune reactivity towards cancer associate neo- and shared epitopes, as well as understanding the influence of cancer therapy on the immune recognition fingerprint in individual patients. Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston. Carl June maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment is now also used with promising results to treat children with refractory acute lymphoblastic leukemia. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors. Paul Parren holds a PhD in molecular immunology from the University of Amsterdam. He was an Associate Professor at The Scripps Research Institute in La Jolla, California, where he studied human antibodies in protection and vaccines against viral infections. In 2002, Paul Parren joined Genmab where he serves in the position of Senior Vice President and Scientific Director. He is also a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden and an Adjunct Professor of Translational Cancer Research at the University of Southern Denmark. In 2016, he was elected President of The Antibody Society, a non-profit trade organization representing the interests of antibody engineering and therapeutics. Paul Parren is an inventor and developer of several therapeutic antibodies, e.g. ofatumumab (ARZERRA, approved in 62 countries), and the DuoBody and HexaBody technologies that enable the development of bispecific and effector-function enhanced antibodies. Ellen Puré is the Grace Lansing Lambert Professor of Biomedical Science and Chair of the Department of Biomedical Sciences at the University of Pennsylvania School of Veterinary Medicine. Ellen Puré received her Baccalaureate degree from Washington University in St. Louis, and her doctorate at the University of Texas Southwestern Medical School and then joined the Faculty at the Rockefeller University. In 1992, Ellen Puré moved to Philadelphia where she was on the Faculty of the Wistar Institute until moving to the University of Pennsylvania in 2013. Her research focuses on the cellular and molecular basis of inflammation and fibrosis. A major focus of her laboratory’s work is to define the role of stromal cells, extracellular matrix (ECM) and matrix remodeling in cancer initiation, progression and metastasis, and to develop novel therapeutic approaches that target the stromal compartment of tumors to use in combination with immune based and other conventional therapies that target malignant cells. 15 CIMT Speakers 16 CIMT Speakers Laszlo Radvanyi Gerold Schuler Timothy Tree EMD-Serono (Merck KgaA) Billerica, USA Universitätsklinikum Erlangen Erlangen, Germany King's College London London, United Kingdom Laszlo Radvanyi is Senior Vice President (SVP), Global Head of Immuno-Oncology R&D at EMD Serono (Merck KgaA, Darmstadt Germany) where he leads pre-clinical and early clinical translational research on tumor immunotherapy combinations and biomarker discovery at the company’s USA (Billerica, MA) and German (Darmstadt) R&D sites. Previously, Dr. Radvanyi was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, M.D. Anderson Cancer Center in Houston and then joined Lion Biotechnologies developing T-cell therapies for solid tumors and leading pre-clinical and process development work resulting in two key IND filings for TIL therapy trials currently underway in metastatic melanoma, head and neck cancer, and cervical cancer. He also performed basic and translational research identifying biomarkers in T-cell therapy, improving the anti-tumor function of expanded T cells, and developing improved manufacturing methods for T-cell therapy. Gerold Schuler is Professor of Dermatology at FriedrichAlexander University Erlangen-Nuremberg and head of the Dept. of Dermatology at University Hospital Erlangen. His main scientific contributions have been i) discovery of the maturation of dendritic cells; ii) identification of GM-CSF as the key cytokine for myeloid dendritic cell differentiation which resulted in the first reproducible generation of dendritic cells from hematopoietic precursors in the mouse and subsequently the development of the current “gold standard” of human dendritic cell generation from monocytes using GM-CSF + IL-4 or IL-13; and iii) identification of CD4+CD25+ regulatory T cells in humans. Gerold Schuler and his research team explore the adoptive transfer of ex vivo generated DC to vaccinate against cancer, and they have established a translational unit including a GMP laboratory with manufacturing license for dendritic cells and mRNA for phase I to phase III trials. Timothy Tree is a specialist in human T-cell immunology with particular expertise in analysing the function of regulatory T cells in human health and disease. Timothy Tree studied Biochemistry at Imperial College London and then completed a PhD at the same institute funded by the World Health Organization investigating the role of the immune system in the pathology associated with infection with the filarial nematode Onchocerca volvulus, which leads to river blindness. His current research interests are focused on understanding the role of pathogenic and regulatory T cells in human health, disease and transplantation. These studies have led to the identification of several novel populations of antigen specific regulatory T cells as well us uncovering an underlying defect in regulatory T cell function in individuals with type 1 diabetes. Matthias Renner Hergen Spits Paul-Ehrlich-Institute Langen, Germany AIMM Therapeutics Amsterdam, The Netherlands Matthias Renner is Scientific Assessor in the Department of Medical Biotechnology at the Paul-Ehrlich-Institute, Germany, where he is involved in the evaluation of clinical trial applications and in national scientific advice procedures for ATMPs. He serves also as expert to the European Medicines Agency (EMA) for the assessment of marketing authorization applications and scientific advices. Matthias Renner has been a member of the Committee for Advanced Therapies (CAT) Gene Therapy Working Party since 2010 and its vice chair since 2011. He is doing research on different aspects of cell and gene therapy and lentivirus biology. Prior to joining PEI in 2009, he served as Department Head for Vector Development and Preclinical Models at Austrianova, Vienna, where he was responsible for developing the company´s gene therapy products. Since 2007, he has also been affiliated with the University of Veterinary Medicine Vienna, serving as group leader at the Institute of Virology until 2008 and as senior lecturer in virology. Hergen Spits is a professor of cell biology at the University of Amsterdam, where he leads a research program on auto immune- and inflammatory diseases. He is also CSO of AIMM therapeutics which develops human monoclonal antibodies. Hergen Spits has made several contributions to the field of human lymphocytes and was the first to describe the phenomenon of redirected killing by human T cells using anti CD3 antibodies. More recent contributions include the first description of Th22 cells and the discovery of human Lymphoid Tissue inducer cell and various other human Innate Lymphoid cell (ILC) subsets. While studying the mechanisms of development of human antibody-producing B cells, his lab also invented an innovative technology to immortalize human and non-human antibody-producing B cells which was used to establish a number of broadly reacting highly neutralizing virus specific antibodies, some of which are in clinical development. Doris Schmitt Per thor Straten PATH Radolfzell, Germany University of Copenhagen Copenhagen, Denmark Doris Schmitt is a communications consultant advising companies in management and sales. A breast cancer diagnosis and cancer in the family made her realize how important it is to be informed about one’s own disease and treatment options. In order to gather information on the latest study results in the mamma carcinoma and non-small-cell lung carcinoma field, she regularly visits cancer congresses at home and abroad. As a volunteer, she supports the executive board of PATH, a breast cancer biobank where tissue taken from breast cancer patients is frozen and stored free of charge in order to make it available to research. In her publications, seminars, and lectures, Doris Schmitt educates physicians, pharmacists, caregivers and patients on the importance of an equal footing between physician and patient. Per thor Straten is Professor at the Department of Immunology and Microbiology of the University of Copenhagen and Director at the Centre for Cancer Immunotherapy (CCIT), Department of Hematology, at the University Hospital Herlev in Denmark. Research programs at CCIT include the characterization of tumor antigens, clinical trials using adoptive cell transfer (ACT) of T cells by in- vitro expansion of tumor infiltrating lymphocytes (TIL), genetic engineering of T cells for ACT aiming at improved homing to - and functionality at - the tumor site. Moreover, a recent direction is focused on exercise as an immune modulator to control tumor growth and incidence. Per thor Straten is a graduate of the University of Copenhagen and The Open University in Milton Keynes, United Kingdom. He is author/coauthor of more than 130 articles and patents in the area of tumor immunology and immunotherapy. IMMUNO-ONCOLOGY Activating and directing the immune system to fight cancer Revealing the Intricacies of IMMUNO-ONCOLOGY AstraZeneca is committed to advance the science of IO combination therapy to deliver life-changing medicines to patients most in need: ► Immunotherapy + Immunotherapy combination ► Immunotherapy + Chemotherapy combination ► Immunotherapy + Small Molecule combination For more information, please visit https://www.azimmuno-oncology.com/ CIMT Speakers ANNUAL MEETING A clinician, a scientist, a pathologist: realising the promise of cancer immunotherapy Satellite symposium sponsored by Wednesday 11 May 2016 13.00–14.00 Rheingoldhalle Congress Center Mainz, Germany John B. Haanen Kenneth Bloom Netherlands Cancer Institute Amsterdam, The Netherlands Human Longevity, Inc. San Diego, USA John B. Haanen is Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology at the Netherlands Cancer Institute. He is also Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre. John Haanen received his medical degree from the University of Leiden, then completed a PhD on human CD4+ helper T cells at the Department of Immunohematology and the Blood Bank of the Leiden University Medical Centre and the DNAX Research Institute in California, USA. He then trained in internal medicine at Leiden University Medical Centre and at Bronovo Hospital in The Hague, the Netherlands. His research focuses on the translation of novel immunotherapy strategies into the clinical practice, especially adoptive cell transfer programs and immune checkpoint blockade. His clinical medical oncology practice is focused on melanoma and renal cell carcinoma patients. Programme Chair: Kenneth Bloom, California, USA Ignacio Duran 13.00–13.05 Welcome and introduction Kenneth Bloom, California, USA Hospital Universitario Virgen del Rocio Seville, Spain 13.05–13.15 Cancer immunotherapy: so far, so good? Ignacio Duran, Seville, Spain 13.15–13.25 Modulating the tumour microenvironment: the future of cancer immunotherapy John Haanen, Amsterdam, The Netherlands 13.25–13.35 Personalising cancer immunotherapy: beyond morphology Kenneth Bloom, California, USA 13.35–13.55 Panel discussion All faculty 13.55–14.00 Summary and close Kenneth Bloom, California, USA This presentation is not intended for physicians practising in the USA INDUSTRY SATELLITE SYMPOSIA SPEAKERS NP/aPDL1/1604/0016 Roche-sponsored satellite symposium at the 14th Cancer Immunotherapy (CIMT) 2016 Annual Meeting Ignacio Durán, M.D., Ph.D., is the Chief of Section and Coordinator of the Urogenital Tumors Programs at Hospital Universitario Virgen del Rocio (Seville. Spain). He earned his M.D. in 1997 at the Universidad de Salamanca in Salamanca, Spain and his Ph.D. in 2005 at the Universidad Complutense in Madrid, Spain, with highest commendation. He trained in Medical Oncology at the Hospital Universitario Son Dureta in Palma de Mallorca, Spain and completed his Fellowship in Drug Development at the Princess Margaret Hospital in Toronto, Canada between 2004-2007. Throughout his career, Dr. Duran has spent significant time in distinguished national and international investigational centers such as the headquarters of the CSIC at the Universidad de Salamanca in Salamanca, Spain, Catholic University of the Sacred Heart in Rome, Italy, Centre Hospitalier Universitaire in Nantes, France, and Memorial Sloan Kettering Cancer Center in New York City. 19 CIMT Speakers Satellite symposium sponsored by Certainly we cannot treat all tumor types. But we are broadening the horizon of cancer treatment. Stephan Grabbe Thomas Tüting University Medical Center Mainz Mainz, Germany University Hospital Magdeburg Magdeburg, Germany Stephan Grabbe is Director and Chairman of the Department of Dermatology at the University Medical Center Mainz, Germany. He studied medicine at the University of Münster, Germany, and graduated with a Ph.D. in dermatology. From 1989-1992, he was a Postdoctoral Research Fellow at Harvard Medical School and Massachusetts General Hospital in Boston, and then became Resident and Research Fellow at the University of Münster. After several years at the Universities of Münster and Essen, he moved to his current position in Mainz. Stephan Grabbe received numerous awards and honors, including a “Heisenberg” fellowship of the German Research Society. In his research, Stephan Grabbe focuses on morphodynamics of the interaction between dendritic cells and T cells, the role of b2 integrins in antigen presentation as well as tumor immunotherapy with dendritic cells and nanoparticles. Thomas Tüting is Professor and Chairman of Dermatology at the University Hospital Magdeburg. In his former position as Associate Professor of Experimental Dermatology and Head of Dermato-Oncology at the University Hospital Bonn, Thomas Tüting pioneered the establishment of novel genetic mouse model systems that combine experimental tools of tumor immunology and tumor biology to adequately portray clinical situations observed in melanoma patients for the preclinical development of novel combinatorial T cell immunotherapies. An important finding was that simultaneous triggering of endosomal and cytosolic antiviral pattern recognition receptors with synthetic oligonucleotides that activate the type I IFN system supports T-cell effector functions in the tumor microenvironment and promotes tumor cell death. Using adoptive T-cell transfer approaches, his group discovered that progressively growing autochthonous melanomas can resist cytotoxic T-cell responses directed against melanocytic differentiation antigens through reversible dedifferentiation in an inflammatory microenvironment. Non-genetic, inflammation-induced phenotypic plasticity of melanoma and immune cells may represent a more general mechanism how melanomas and other tumor entities resist various forms of cytotoxic therapies. Ralf G. Meyer St.-Johannes-Hospital Dortmund Dortmund, Germany Ralf G. Meyer is Head of the Department of Internal Medicine at the St.-Johannes-Hospital in Dortmund, Germany. In his doctoral thesis in Immunology at the group of Diethard Gemsa, Marburg as well as in the laboratory of J. J. Oppenheim at the National Cancer Institute, he focused on the role of chemokines in Influenza A-infections. Between 1996 and 2002, he worked at the department of Internal Medicine at the Johannes Gutenberg-University Mainz, Germany, and specialized in hematology. In Mainz, he focused his research on immune-response analyses in the research group of Thomas Woelfel. During his tenure at the hematology department, he focused his research interest on allogeneic stem cell transplantation and founded his own research group in 2007 in addition to his clinical work as a hemato-/ oncologist at the university hospital. Ralf Meyer and his team focused on allo-immune responses and the role of antigen-presenting cells in GvHD. In 2013, he was promoted to head the hematopoietic stem cell transplantation program at the 3rd Medical Department in Mainz. 20 Immuno - Oncology by Bristol-Myers Squibb 2016 2015 2011 immunooncology.com ONCDE15PR02443-01 CIMT Program CIMT Program Session overview FLOOR PLAN & PROGRAM OVERVIEW DAY 1 - MAY 10 08:00 - 08:30 REGISTRATION PLENARY SESSION 3 Congress Hall Therapeutic Vaccination 08:30 - 09:00 Meeting Location DAY 2 - MAY 11 Congress Hall WELCOME ADDRESS Congress Hall 10:00 - 10:30 10:30 - 11:00 CIMT ENDEAVOUR Watford Room 09:00 - 09:30 09:30 - 10:00 DAY 3 - MAY 12 Congress Hall COFFEE BREAK PLENARY SESSION 1 SHORT TALK S ESSIONS I, II, III Tumor Microenvironment Gutenberg A & B; Congress Hall Congress Hall PLENARY SESSION 5 Novel Technologies for Immune Assessment COFFEE BREAK SHORT TALK SESSIONS IV, V, VI, VII 11:00 - 11:30 REGULATORY RESEARCH SESSION Congress Hall Gutenberg A & B 11:30 - 12:00 West Foyer Congress Hall Gutenberg B Gutenberg A North Foyer LUNCH LUNCH 12:00 - 12:30 INDUSTRY SATELLITE I 12:30 - 13:00 Bristol-Myers Squibb Congress Hall INDUSTRY SATELLITE II 13:00 - 13:30 Rhine Foyer 13:30 - 14:00 Roche Congress Hall PLENARY SESSION 2 Improving Immunity Upper Floor 14:00 - 14:30 Congress Hall 14:30 - 15:00 MEET THE EDITORS Congress Hall PLENARY SESSION 4 Cellular Therapy PLENARY SESSION 6 Congress Hall Antibodies Registration Lower Floor East Foyer Dijon Room Watford Room 15:00 - 15:30 POSTER SESSION I AND COFFEE BREAK 15:30 - 16:00 Foyer 16:00 - 16:30 16:30 - 17:00 Congress Hall POSTER SESSION II AND COFFEE BREAK EU CONSORTIA SESSION Gutenberg A Foyer 17:00 - 17:30 17:30 - 18:00 18:00 - 18:30 VOICE OF THE PATIENTS Congress Hall KEYNOTE LECTURE Congress Hall 18:30 - 19:00 CIMT MEMBERS MEETING Dijon Room 19:00 - 19:30 19:30 - 20:00 20:00 - 24:00 22 LUNCH SOCIAL EVENT & AWARDS CEREMONY Rhine Foyer CIMT Program Glioma Actively Personalized Vaccine Consortium GAPVAC presents: PRELIMINARY DATA ON SAFETY, FEASIBILITY AND BIOLOGICAL ACTIVITY Glioblastoma (GB) is the most common type of malignant brain tumor with very poor prognosis and a high unmet medical need. The Glioma Actively Personalized Vaccine Consortium (GAPVAC) is a European consortium aiming to take personalized cancer immunotherapy to the next level by generating individual biomarker-tailored therapeutic vaccines for patients with glioblastoma. Each patient participating in the GAPVAC-101 phase I clinical trial receives two actively personalized vaccines (named APVAC). APVAC1 consists of patient-tailored tumor-associated HLA-peptides selected from a pre-manufactured warehouse of approx. 60 antigens shared by a number of glioblastoma patients. APVAC2 vaccine targets patient tumor-specific mutations or over-presented peptides and is de novo manufactured for every patient. ANNUAL MEETING PROGRAM SCHEDULE CIMT 2016 Day 1 – May 10 08:00-09:30 Foyer REGISTRATION Sign-in and badge pickup 09:30-10:00 Congress Hall Five European authorities have approved the GAPVAC-101 phase I study and patients are enrolled in six centers across Europe. As of today 13 patients have been enrolled to the trial from which ten have already been treated with at least one APVAC. After the successful transfer of this novel and ambitious concept of actively personalized cancer immunotherapy into the clinic, first data with regard to safety, feasibility and biological activity will be presented at this year´s CIMT Annual Meeting. CIMT is a consortium partner and the primary dissemination platform for results of the GAPVAC trial. If you want to learn more about the project, please visit the following presentations as well as the GAPVAC webpage www.gapvac.eu: �Poster 40: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma 10:00-11:30 Congress Hall Immatics biotechnologies GmbH (Coordinator) Heidelberg University Hospital (Chief Investigator) BioNTech (Vice Coordinator) Geneva University Hospital (Co-Chief Investigator) University of Tübingen, Germany Barcelona Vall d´Hebron University Hospital BCN Peptides S.A., Spain Leiden University Medical Centre, Netherlands Technion Israel Institute of Technology Copenhagen Herlev Hospital, Denmark CIMT University of Southampton, UK Christoph Huber, CIMT PLENARY SESSION 1 Tumor Microenvironment Chairs: Michele Maio (Siena, Italy), Rienk Offringa (Heidelberg, Germany) 10:00-10:30 Mikael Pittet, Harvard Medical School "Cancer-host cell interactions: analysis in context" 10:30-11:00 Ellen Puré, University of Pennsylvania “The functional heterogeneity of tumor stroma: implications for modulating antitumor immunity and enhancing immunotherapy” 11:00-11:30 Vincenzo Bronte, University of Verona "Immune suppressive and immune stimulating monocytes in cancer" � Talk on May 11, 4 p.m.: GAPVAC: First results from a personalized peptide vaccination study in glioblastoma Thirteen institutions from academia and industry, supported by the European Commission’s 7th framework program (FP7) 2012, are joint in GAPVAC to realize this highly innovative project: WELCOME ADDRESS 11:30 -13:00 Foyer LUNCH Lunch boxes and drinks University of California San Francisco (UCSF) 25 CIMT Program CIMT Program Day 1 – May 10 12:00 -13:00 Congress Hall Day 1 – May 10 INDUSTRY SATELLITE I organized by: 12:00-12:20 Thomas Tüting, University Hospital Magdeburg "Introducing new horizons in cancer immunotherapy" 12:20-12:40 Ralf Meyer, St. Johannes Hospital Dortmund "Immunotherapeutic approaches in lymphoma treatment" 12:40 -13:00 Stephan Grabbe, University Medical Center Mainz "The next chapter in I-O: combination strategies for the treatment of malignant melanoma" Congress Hall organized by: 13:30 -14:00 Hergen Spits, Amsterdam Medical Center “B cell responses in cancer immunotherapy” 14:00-14:30 George Prendergast, Lankenau Institute for Medical Research "IDO pathways in cancer therapy" 14:30 -15:00 Per thor Straten, University of Copenhagen "Suppression of tumor growth and incidence by voluntary exercise" Foyer 15:00-17:30 "Clinical studies and patient advocates" Chair: Eva Winkler (NTC, Heidelberg) 18:00-19:00 Congress Hall Doris Schmitt, PATH "How can patient experts support treatment protocols and informed consent?" KEYNOTE ADDRESS Chair: Christoph Huber (Mainz, Germany) Wolf Hervé Fridman, Centre de Recherche des Cordeliers "The diversity of immune microenvironments in human cancers" Improving Immunity Chairs: Hansjoerg Schild (Mainz, Germany), Andreas Diefenbach (Mainz, Germany) VOICE OF THE PATIENTS PLENARY SESSION 2 15:00 -15:30 Congress Hall Chair: Dirk Jäger (Heidelberg, Germany) 13:30 -15:00 17:30 -18:00 "Immuno-Oncology: Transforming the future and raising the bar in cancer treatment” COFFEE BREAK Coffee and snacks Foyer POSTER SESSION I SEE WHAT INNOVATIONS IN IMMUNO-ONCOLOGY COULD MEAN FOR YOUR PATIENTS Our research and development team takes a broad and integrated approach and develops new immunotherapy-based treatments that target cancer. This approach involves leveraging a robust and diverse pipeline of molecules that target the tumor and the immunosuppressive microenvironment, and developing rational combination strategies with an emerging internal pipeline of molecules that modulate T cell function. We are also investigating novel approaches to redirect activated T cells to tumors. Therapeutic Vaccination, Immunomonitoring, Cellular Therapy To find out more about the immunotherapies we currently have in clinical development, go to LillyOncologyPipeline.com. ON98796 26 04/2016 © Lilly USA, LLC 2016. All rights reserved. 27 CIMT Program CIMT Program Day 2 – May 11 08:00-09:30 Congress Hall Day 2 – May 11 PLENARY SESSION 3 Therapeutic Vaccination Chairs: Carl Figdor (Nijmegen, The Netherlands), Ugur Sahin (Mainz, Germany) 08:00-08:30 Darrell J. Irvine, MIT "Recruiting synergistic innate and adaptive immune responses against tumors" 08:30-09:00 09:00-09:30 08:00-12:00 Watford Room Chairs: Ralf-Holger Voss (Mainz, Germany), Isabel Poschke (Heidelberg, Germany) 10:15 -10:30 Cornelis Melief, Leiden University Medical Center "Therapeutic vaccinaton as a component in combination treatment of cancer" Anett Pfeiffer (#114), Paul-Ehrlich-Institute "Towards in vivo delivery of chimeric antigen receptors" 10:30-10:45 Oliver Schoor (#120), Immatics Biotechnologies GmbH "On- and off target toxicity profiling for adoptive cell therapy by mass spectrometrybased immunopeptidome analysis of primary human normal tissues" 10:45 -11:00 Barbara F. Schörg (# 121), Eberhard Karls University of Tübingen "Combining tumor antigen (TA) specific Th1 cells with immune checkpoint blocking antibodies induces tumor regression in advanced carcinomas" 11:00-11:15 Petra Simon (#124), BioNTech Cell & Gene Therapies GmbH "Retrieval of functional TCRs from single neo-antigen-specific T cells: Toward individualized TCR-engineered therapies" 11:15 -11:30 Parvez Vora (#125), McMaster University "Novel immunotherapies for recurrent glioblastoma: The efficacy of CD133 BiTEs and CAR T cells in preclinical models" CIMT ENDEAVOUR 08:10 -09:00 Session 1: Keynote Lothar Germeroth, Juno Therapeutics Session 2: From Science to Products - Change of Perspectives Chairs: Andrea Schilz (Ci3), Jutta Heix (Oslo Cancer Cluster) CIMT-Scientist Presentations: Nadica Mensali, Oslo University Hospital Radiumhospitalet "Csk overexpression makes T cell dummy" Nico Büttner, Universitätsklinikum Freiburg "The HLA-associated phosphoproteome as a new target for immunotherapy against hepatocellular carcinoma" Expert Advice Panel: Stefan Ries (Roche), Georg Schnappauf (Schnappauf & Partner), David Philipps (SR One) 10:10 -10:45 Coffee break 10:45 -11:45 Session 3: Company Stories/Successful Deals Chair: Rainer Wessel (Ci3) 11:45 -12:00 Foyer David Philipps, SR One "Corporate venture investing in life sciences" Derek Jantz, Precision BioSciences "Precision BioSciences: a 10-year old startup" Cedrik Britten, CIMT Closing words 10:00-11:30 Gutenberg A Coffee and snacks supported by: SHORT TALK SESSION II New Targets, Leads and Biomarkers Chairs: John Castle (Basel, Switzerland), Angelika Riemer (Heidelberg, Germany) 10:00-10:15 Mark Ayers (#168), Merck & Co., Inc. "Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab in patients with advanced solid tumors" 10:15 -10:30 Michal Bassani-Sternberg (#169), University of Lausanne/CHUV "Direct identification of neo-epitopes using in-depth immunopeptidomics of melanoma tissues for the development of anti-tumor immunotherapies" 10:30-10:45 Marta Ilecka (#181), DKFZ Heidelberg "Antigen-armed antibodies in the treatment of B-cell lymphoma" 10:45 -11:00 Maria Kreuzberg (#185), Ganymed Pharmaceuticals AG "IMAB027-DM1 and IMAB027-vcMMAE, CLDN6-specific antibody-drug conjugates, are effective against human CLDN6-positive cancer cells in vitro and in vivo" 11:00-11:15 Hideho Okada (#196), University of California San Francisco "Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation" 11:15 -11:30 Rita Pfeifer (#199), Miltenyi Biotec "Sialyl Glycolipid Stage-Specific Embryonic Antigen 4 (SSEA4) – a novel target for CAR T cell therapy of solid cancers" COFFEE BREAK 28 Cellular Therapy Gerold Schuler, Universitätsklinikum Erlangen "Dendritic cells as cancer vaccines: taking nature´s adjuvant to a phase III trial" Björn Philipp Kloke, CIMT Welcome and introduction 09:00-10:10 SHORT TALK SESSION I Bruce McCreedy (# 108), Precision BioSciences, Inc. "Allogeneic CAR-T cells gene edited to insert an anti-CD19 CAR into the TCR alpha locus target and kill CD19+ Raji lymphoma tumors in vitro and in vivo without causing GvHD" 08:00-08:10 09:30-10:00 Congress Hall 10:00-10:15 R&D workshop on the translation and commercialization of cancer immunotherapies and diagnostics 10:00-11:30 29 CIMT Program CIMT Program Day 2 – May 11 10:00-11:30 Gutenberg B Day 2 – May 11 SHORT TALK SESSION III Tumor Biology & Interaction with the Immune System Chairs: Viktor Umansky (Heidelberg, Germany), Mustafa Diken (Mainz, Germany) 14:00-15:30 Ruby Alonso (#247), Institute Curie, Inserm U932 "Infectious" tolerance transforms tumor antigen specific naive CD4 T cells into induced Tregs in a spontaneous lung tumor model" 10:15 -10:30 Marcel A. Deken (#259), Netherlands Cancer Institute "Synergy of anti-PD-1 in combination with targeted therapy is mediated by CD8+ T cells" 10:30-10:45 Andrew Furness (#273), UCL Cancer Institute "Characterisation of immune and tumour-specific neoantigen landscapes informs optimal therapeutic targeting in non-small cell lung cancer" 10:45 -11:00 Remi Ramjiawan (#302), Harvard Medical School/ Massachusetts General Hospital "c xcr4 inhibition in tumor microenvironment facilitates anti-program death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice" 11:00-11:15 Sunil Kumar Saini (#304), National Veterinary Institute, Technical University of Denmark "Identification and characterization of neoepitopes associated with individual mutational landscape in non-small cell lung cancer" 11:30 -14:00 Foyer Els Verdegaal (#325), Leiden University Medical Center "A changing neo-antigen landscape in human melanoma under T cell pressure" LUNCH Lunch boxes and drinks 13:00 -14:00 Congress Hall Chairs: Michael Kalos (New York, USA), Cornelis Melief (Leiden, The Netherlands) 14:00-14:30 Carl June, University of Pennsylvania "Adoptive T-cell therapy for cancer" 14:30 -15:00 Chiara Bonini, Fondazione San Raffaele del Monte Tabor "TCR gene editing for hematological malignancies" 15:00-15:30 Robert Hawkins, Cancer Research UK "Adoptive T-cell therapy with tumor infiltrating lymphocytes" 15:30 -18:00 15:30 -18:00 16:00-17:30 Foyer COFFEE BREAK Coffee and snacks Foyer POSTER SESSION II New Targets & New Leads, Tumor Biology and Interaction with the Immune System, Improving Immunity Gutenberg A EU CONSORTIA SESSION Ongoing EU-funded cancer immunotherapy consortia Chairs: Rienk Offringa (Heidelberg, Germany), Jan van de Loo (Brussels, Belgium) 16:00-16:05 Rienk Offringa, German Cancer Research Center "Fostering interaction and synergy between ongoing EU cancer immunotherapy consortia" 16:05-16:25 Harpreet Singh, Immatics Biotechnologies "GAPVAC: first results from a personalized peptide vaccination study in glioblastoma" INDUSTRY SATELLITE II A clinician, a scientist, a pathologist: realising the promise of cancer immunotherapy PLENARY SESSION 4 Cellular Therapy 10:00-10:15 11:15 -11:30 Congress Hall Chair: Kenneth Bloom (San Diego, USA) organized by: 16:25 -16:45 Ann White, University of Southampton "IACT: The human IgG2 format imparts potent agonistic properties to immunostimulatory antibodies" 13:00-13:05 Kenneth Bloom "Welcome and introduction" 16:45-17:05 13:05-13:15 Ignacio Duran, Virgen del Rocio University Hospital "Cancer immunotherapy: so far, so good?" Fred Falkenburg, Leiden University Medical Center "T-Control: therapy of hematological malignancies using streptamer-selected cell products" 17:05 -17:10 13:15 -13:25 John Haanen, Netherlands Cancer Institute "Modulating the tumour microenvironment: the future of cancer immunotherapy" Jan van de Loo, European Commission "EU cancer (immunotherapy) consortia: what we are looking for in the next round" 17:10 -17:20 13:25 -13:35 Kenneth Bloom, Human Longevity, Inc. "Personalising cancer immunotherapy: beyond morphology" Zlatko Trajanoski, Medical University of Innsbruck "APERIM: Advanced bioinformatics platform for PERsonalized cancer IMunotherapy" 17:20 -17:30 13:35 -13:55 Panel discussion Sebastian Kobold, Ludwig Maximilians University Munich "IMMUTRAIN: training network for the immunotherapy of cancer" 13:55 -14:00 Kenneth Bloom "Summary and close" 30 31 CIMT Program CIMT Program Day 2 – May 11 Day 3 – May 12 Dijon Room 18:30-19:30 CIMT MEMBERS MEETING Foyer 20:00-24:00 08:30-10:00 General Members Assembly of the Asscociation for Cancer Immunotherapy SOCIAL EVENT AND AWARDS CEREMONY Drinks, food and music CIMT POSTER AWARDS SUPPORTED BY Congress Hall Novel Technologies for Immune Assessment Chairs: Sjoerd van der Burg (Leiden, The Netherlands), Vincenzo Bronte (Verona, Italy) 08:30-09:00 Timothy Tree, King's College London "Measuring regulatory T cell phenotype and function in human health and disease" 09:00-09:30 Sine Reker Hadrup, Technical University of Denmark "Next-generation detection of cancer-responsive T cells" 09:30-10:00 Giuliano Elia, Philochem "A phase III trial of the intralesional application of L19IL2/L19TNF in stage IIIB/C melanoma patients" 10:00-10:30 Foyer 10:30-11:45 f ir s t- in - class immunother apies against cancer and we believe individualized treatments accessible to Gutenberg A SHORT TALK SESSION IV Improving Immunity Chairs: Kris Thielemans (Brussels, Belgium), Per thor Straten (Herlev, Denmark) 10:30-10:45 Sara Colombetti (#220), Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich "PD-L1 checkpoint blockade enhances anti-tumor activity of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors" 10:45 -11:00 Timothy Cripe (#221), Nationwide Children's Hospital "Seprehvir, an oncolytic herpes viroimmunotherapeutic, enhances therapeutic efficacy of T cell checkpoint inhibition in solid tumors by increasing T cell recruitment and remodeling the immunosuppressive microenvironment" 11:00-11:15 Nina Eissler (#224), Karolinska Institutet "Release of IFN-γ induced chemokines provides the key to efficient combination immunotherapy of anti-PD-1 antibody with CSF-1R inhibitor" 11:15 -11:30 Jaap Kwekkeboom (#231), Erasmus MC "Functionality of tumor-infiltrating T cells in hepatocellular carcinoma can be enhanced by blocking several co-inhibitory pathways" 11:30 -11:45 David Richards (#236), Apogenix AG "Hexavalent agonists targeting receptors of the tumor necrosis factor superfamily: TRAIL, CD40L, CD27L and beyond" should be broadly every single patient. COFFEE BREAK Coffee and snacks We develop PLENARY SESSION 5 PIONEERS AT WORK 32 WWW.BIONTECH.DE 33 CIMT Program CIMT Program Day 3 – May 12 10:30-11:45 Gutenberg B Day 3 – May 12 SHORT TALK SESSION V Therapeutic Vaccination Chairs: Sebastian Kreiter (Mainz, Germany), Ulrich Kalinke (Hanover, Germany) 11:45 -13:15 Gutenberg A SHORT TALK SESSION VI Immunomonitoring Chairs: Cecile Gouttefangeas (Tübingen, Germany), Marij Welters (Leiden, The Netherlands) 10:30-10:45 Marcin Cebula (#013), Helmholtz Centre for Infection Research "TLR9 stimulation is required for recall of functional immune memory response against neo-antigen relapse in liver" 11:45 -12:00 Amalie Kai Bentzen (#140), Technical University of Denmark "Next-generation detection of cancer-responsive T cells using DNA barcode-labeled peptide-Major Histocompatibility Complex I multimers" 10:45 -11:00 Naozumi Harada (#032), Mie University Graduate School of Medicine "A novel combination immunotherapy consisting of tumor-associated macrophagetargeted vaccine, TLR agonist, and neoantigen-specific T cell transfer cures tumor highly resistant to immune checkpoint blockade" 12:00-12:15 Coco de Koning (#146), UMC Utrecht "CD4+ T-cell immunomonitoring after hematopoietic cell transplantation: identifying patients at risk for virus-predicted adverse outcomes" 11:00-11:15 Zaima Mazorra (#045), Center of Molecular Immunology Havana "Immunological results obtained in castration-resistant prostate cancer patients treated with an EGFR-based vaccine." 12:15 -12:30 Gabriele Niedermann (#152), University Clinics Freiburg "Noninvasive ImmunoPET imaging of the PD-1/PD-L1 checkpoint in naïve and irradiated tumor-bearing mice" 11:15 -11:30 Anne De Groot (#048), EpiVax, Inc. "Improved mutanome-directed cancer immunotherapy by immunoinformatic analysis of cancer neo-epitopes for regulatory T cell activation potential" 12:30-12:45 Paulo Rodrigues-Santos (#156), Faculdade de Medicina da Universidade de Coimbra "Immune monitoring of natural killer cells in chronic myeloid leukemia: split anergy status depend on tyrosine kinase inhibitor therapy" 11:30 -11:45 Zane Yang (#074), Inovio Pharmaceuticals, Inc. "Immunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in Human Papillomavirus (HPV) associated Head and Neck Squamous Cell Carcinoma (HNSCCa): Interim results" 12:45 -13:00 Julien Schmidt (#157), Ludwig Center of the University of Lausanne "Isolation and analysis of tumor-specific CD8 and CD4 T cells with high affinity, reversible pMHC multimers" 13:00-13:15 Sine Reker Hadrup, National Veterinary Institute, Technical University of Denmark "CIP – Immunoguiding activities" 10:30-13:00 Congress Hall REGULATORY RESEARCH SESSION "Adoptive cellular therapies" Chairs: Harpreet Singh (Tübingen, Germany), Michael Kalos (New York, USA) 10:30-10:40 Ulrich Kalinke, Chairman CIMT Regulaory Research Group Introduction 10:40-11:15 Carl June, University of Pennsylvania "Challenges in early-stage development of adoptive cell therapies" 11:15 -11:50 Gwen Binder-Scholl, Adaptimmune "Challenges in advanced-stage development of adoptive cell therapies" 11:50 -12:25 Matthias Renner, Paul Ehrlich Institute "Regulation of adoptive cellular therapies in Europe" 12:25 -13:00 Panel discussion, with presenters and additional panelists Ulrich Kalinke, Carl June, Gwen Binder-Scholl, Matthias Renner, Cedrik Britten (Glaxo Smith Kline), Peter Bross (FDA CBER) 34 11:45 -13:00 Gutenberg B SHORT TALK SESSION VII Clinical Trials Chairs: Anthony Kong (Birmingham, United Kingdom), Stephan Grabbe Mainz, Germany) 11:45 -12:00 Theresa Bunse(#010), German Cancer Research Center (DKFZ) "Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas" 12:00-12:15 Markus Löffler (#43), University of Tübingen "Personalized multi-peptide vaccination induces immune responses associated with long term survival in a patient with metastatic intrahepatic cholangiocarcinoma" 12:15 -12:30 Matthias Miller (#047), BioNTech AG "IVAC® MUTANOME – a first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma" 12:30-12:45 Raquel Gomez-Eerland (#090), NKI-AVL "Adoptive transfer of autologous T cells modified with a MART-1 specific TCR in advanced stage melanoma patients" 12:45 -13:00 Tanja D. de Gruijl (#222), VU University Medical Center "Local adjuvant treatment of clinical stage I-II melanoma with CpG-B/GM-CSF improves distant recurrence-free survival: long-term follow-up of three randomized controlled phase II trials" 35 CIMT Program Day 3 – May 12 Foyer 13:00 -14:30 LUNCH Lunch boxes and drinks Congress Hall 13:30 -14:30 MEET THE EDITORS 14:30 -16:00 Cancer Research, George Prendergast Clinical Cancer Research, Ignacio Melero Journal for Immunotherapy of Cancer, Cornelis Melief Science Translational Medicine, Yevgenia Nusinovich Congress Hall nCounter® PanCancer Immune Profiling Panel Explore - Understand - Create PLENARY SESSION 6 Antibodies Chairs: Ignacio Melero (Pamplona, Spain), Özlem Türeci (Mainz, Germany) 14:30 -15:00 Rony Dahan, The Rockefeller University "Requirement of FcγR pathways for the therapeutic activity of immunomodulatory antibodies" 15:00-15:30 Paul Parren, Genmab "The molecular mechanism of complement activation by IgG: from scientific insight to therapeutic antibody drug design" 15:30 -16:00 Laszlo Radvanyi and Kin-Ming Lo, EMD-Serono (Merck KgaA) "PD-1/PD-L1 and beyond: new approaches and targets to overcome tumor immune" A Multiplexed Gene Expression Approach To Profiling Cancer Immunology The nCounter PanCancer Immune Profiling Panel is a novel new gene expression panel that enables researchers to develop profiles of the human immune response in all cancer types. In collaboration with cancer immunologists around the globe, our new 770 gene panel combines markers for 24 different immune cell types, 30 common cancer antigens and genes that represent all categories of immune response including key checkpoint blockade genes. Explore Infiltrating Cell Types Understand Immune Pathway Activity Create Profiles of the Immune Response in Any Cancer Type A uniquely simple and reliable way to measure gene expression in Cancer. The highly multiplexed, enzyme-free*, direct digital detection technology of the nCounter System ensures that the nCounter PanCancer Immune Profiling Panel provides high quality data from all sample types including FFPE and PBMCs. The system features and easy-to-use workflow and simplified data analysis. * Single Cell assay requires reverse transcription and amplification prior to analysis on the nCounter System. www.nanostring.com/pancancer_immune www.nanostring.com | [email protected] | 1 888 358 6266 © 2014 NanoString® Technologies. All rights reserved. NanoString®, NanoString Technologies®, the NanoString logo, and nCounter® are registered trademarks of NanoString Technologies, Inc., (“NanoString”) in the United States and/or other countries. 36 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. CIMT Information ANNUAL MEETING 2016 INDUSTRY EXHIBITORS Meet us at Verapido’s CIMT Industry Exhibition booth, May 10-12, and at CIMT Endeavour, May 11, 8:00-12:00 See our Abstract Number P219 and our poster at the ‘Improving Immunity’ Poster Session, May 11, 15:30-18:00 A Novel, Convenient Intradermal Injection Device Vaccines, Immunotherapies for Intracutaneous Peptides, Proteins, Antibodies Injections Insulin and other Hormones Nucleic Acids Hahn-Schickard Verapido Medical GmbH Wilhelm-Schickard-Straße 10 D-78052 Villingen-Schwenningen Baden-Württemberg, Germany www.Hahn-Schickard.de Contact Dr. med. Markus Clemenz Telephone: +49 7721 943-141 E-mail: [email protected] [email protected] www.Verapido.com 39 CIMT Information CIMT Information [ A ] Acris Antibodies - . . . . . . . . . . . B006 OriGene EV Schillerstraße 5 32052 Herford, Germany www.acris-antibodies.com Antikörper, Proteine, C DNA Klone ANNUAL MEETING 2016 INDUSTRY EXHIBITORS Adaptive Biotechnologies . . . . . . B002 1511 Eastlake Ave E, Suite 200 Seattle, Washington 98102, USA Advanced Cell Diagnostics . . . . . B015 Via Calabria 15 20090 Segrate, Italy www.acdbio.com RNAscope AID GmbH. . . . . . . . . . . . . . . . . A016 Ebinger Straße 4 72479 Strassberg, Germany www.aid-diagnostika.com Imerge Analyzer Rheinufer B017 B016 B011 B012 B018 B014 B013 B020 B019 B015 Main Entrance Rhine Foyer B008 B007 Watford- and Dijon-Room B004 B006 B003 Astra Zeneca GmbH. . . . . . . . . . B012 Tinsdaler Weg 183 22880 Wedel, Germany www.astazeneca.de www.azimmuno-oncology.com Combinations in Immuno-Oncology Participants Registration Wardrobe B005 B010 AmpTec GmbH . . . . . . . . . . . . . B013 Königstraße 4 A 22762 Hamburg, Germany www.amp-tec.com Synthetische mRNA [ B ] Beckman Coulter GmbH . . . . . . A016 Europark Fichtenhain 47807 Krefeld, Germany www.beckman.com Flow Cytometry B001 A022 A021 A002 A020 A019 A003 City Hall Platform Jockel-Fuchs-Platz Underground Car Park A007 Catering A006 North Foyer Congress Hall A005 Gutenberg A and B A008 A009 A016 A011 A015 A012 C001 A013 Becton Dickinson GmbH. . . . . . B005 Tullastraße 8-12 69126 Heidelberg, Germany www.bdbiosciences.com/us/home BioLegend . . . . . . . . . . . . . . . . . B020 9727 Pacific Heights Blvd. San Diego, CA 92121, USA www.biolegend.com BIO-SYS GmbH. . . . . . . . . . . . . . A005 Kiefernweg 10 61184 Karben, Germany www.biosys.de Bioreader® A017 A010 South Foyer A018 A004 West Foyer 14 A0 Biozol. . . . . . . . . . . . . . . . . . . . . B019 Diagnostica Vertrieb GmbH Obere Hauptstraße 10b 85386 Eching, Germany www.biozol.de MHC Tetramere/Monomere, Antikörper, ELISA, Proteine [ C ] Rheinstraße 40 Charles River Research . . . . . . . . B007 Models and Services Sandhofer Weg 7 97633 Sulzfeld, Germany www.criver.com Alzet Osmotische Pumpen, Research Models, Jax Mice Models CI3 Management UG . . . . . . . . . A014 Hölderlinstraße 8 55131 Mainz, Germany www.ci-3.de CTL Europe GmbH. . . . . . . . . . . A022 Hans-Boeckler-Straße 19-29 53225 Bonn, Germany www.immunospot.eu ELISPOT ANALYZERS, KITS, SERUMFREE MEDIA, CRYOPRESERVED PBMC [ E ] eBioscience, an . . . . . . . . . . . . . A004 Affymetrix company Campus Vienna Biocenter 2 1030 Vienna, Austria www.ebioscience.com Forschungsreagenzien [ J ] [ P ] JPT Peptide Technologies . . . . . . B008 Volmerstraße 5 12489 Berlin, Germany www.jpt.com Peptide PANTEC Biosolutions AG. . . . . . A009 Industriering 21 9491 Ruggell, Liechtenstein www.pantec-biosolutions.com P.L.E.A.S.E. Professional Lasergerät [ L ] Lilly Oncology. . . . . . . . . . . . . . B010 Lilly Corporate Center, Indianapolis IN 46285, USA www.lillyoncology.com Lophius Biosciences GmbH . . . . . B001 Josef-Engert-Straße 13 93053 Regensburg, Germany www.lophius.com Produkte und Serviceleistungen für die immunologische Forschung und Diagnostik [ M ] PEPperPRINT. . . . . . . . . . . . . . . A017 Rischerstraße 12 69123 Heidelberg, Germany www.pepperprint.com Peptide Microarrays, Epitope Mapping, Serum Signature Analysis Personalis Inc.. . . . . . . . . . . . . . A012 7330 O'Brien Drive CA 94025 Menlo Park, USA www.personalis.com NGS-Services for Immuno-Oncology and Cancer Dx PeproTech GmbH. . . . . . . . . . . . A015 Oberaltenallee 8 22081 Hamburg, Germany www.peprotech.com Proteine, Antikörper, ELISA, …, Medien Mabtech AB. . . . . . . . . . . . . . . . B004 Augustendalsvägen 19 13152 Nacka Strand, Sweden www.mabtech.com ELISpot, ELISA, Antibodies PromoCell GmbH. . . . . . . . . . . . A018 Sickingenstraße 63/65 69126 Heidelberg, Germany www.promocell.com Meso Scale Discovery.. . . . . . . . C001 1601 Research Blvd 20850, Rockville, USA www.mesoscale.com U-PLEX, S-PLEX, V-PLEX Proteintech Europe Limited. . . . A002 Manchester Science Park, Kilburn House Manchester M15 6SE, United Kingdom www.ptglab.com Autibodies + ELISA Kits B002 East Foyer A001 CENIBRA GmbH . . . . . . . . . . . . A011 Große Straße 17 49565 Bramsche, Germany www.cenibra.de Cellometer Cell Counter, Celigo Imaging Cellometer, CQ1 High Content Analyser CellGenix GmbH . . . . . . . . . . . . B017 Am Flughafen 16 79108 Freiburg, Germany www.cellgenix.com Cytokines, Media,Supplements+ alls Essen Bioscience. . . . . . . . . . . . B014 BioPark, Broadwater Road AL73AX, Welwyn Garden City, United Kingdom www.essenbioscience.com Miltenyi Biotec GmbH. . . . . . . . B011 Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach, Germany www.miltenyibiotec.com EUFETS GmbH. . . . . . . . . . . . . . A020 Vollmersbachstraße 66 55743 Idar-Oberstein, Germany www.eufets.com [ N ] [ G ] GE Healthcare Europe. . . . . . . . A019 GmbH Munzinger Straße 5 79111 Freiburg, Germany www.gelifesciences.com Xuri [ I ] IBA GmbH . . . . . . . . . . . . . . . . . A003 Rudolf-Wissell-Straße 28 37079 Göttingen, Germany www.iba-lifesciences.com www.fabian-online.com FaBian®, CELLina® Immudex. . . . . . . . . . . . . . . . . . A001 Fruebjergvej 1 DK-2100 Copenhagen, Denmark www.immudex.com Dextramers NanoString Technologies. . . . . . B003 Germany GmbH Alsterwiete 3 20099 Hamburg, Germany www.nanostring.com Nano String Technologies nCounter Analysis System and NanoString Technologies Codesets New England Biolabs. . . . . . . . . A006 Cell Signaling Technology Brüningstraße 50, Gebäude B 852 69926 Frankfurt am Main, Germany www.neb-online.de Reagenzien für die Krebsforschung, Zell- und Molekularbiologie [ O ] OLS, OMNI Life Science. . . . . . . A010 GmbH & Co KG Karl-Ferdinand-Braun-Straße 2 28359 Bremen, Germany www.ols-bio.de xCELLigence, NovoCyte, CASY [ S ] Sino Biological Inc. . . . . . . . . . . A013 Suite B-210-C, 14 Zhong He Street, BDA Beijing 100176, China www.sinobiological.com Proteins, Antibodies, cDNA Clones, Elisa Kits, Resins, and other Research Tools [ T ] ThermoFisher Scientific . . . . . . A007 Frankfurter Straße 129B 64293 Darmstadt, Germany www.thermofisher.com Flow Cytometry The Jackson Laboratory . . . . . . B018 600 Main Street 04609 Bar Habor, Maine, USA www.jax.org TRON - . . . . . . . . . . . . . . . . . . . A021 Translationale Onkologie an der Universitätsmedizin der Joh. Gutenberg Universität Mainz Freiligrathstraße 12 55131 Mainz, Germany www.tron-mainz.de [ V ] Verapido Medical GmbH . . . . . . A008 Wilhelm-Schickard-Str. 10 78052 Villingen-Schwenningen, Germany www.verapido.com Dermaject Intradermales Injektionsgerät 41 CIMT Information POSTER AWARD POSTER PRESENTATIONS Abstracts have been selected for poster presentation in six categories. Therapeutic Vaccination Cellular Therapy Immunomonitoring Poster Session I, May 10, 15:00-17:30, Foyer New Targets & New Leads Poster Session I, May 10, 15:00-17:30, Foyer Poster Session I, May 10, 15:00-17:30, Foyer Poster Session II, May 11, 15:30-18:00, Foyer Improving Immunity Poster Session II, May 11, 15:30-18:00, Foyer 2016 CIMT Poster Award SPONSORED BY Tumor Biology & Interaction with the Immune System Poster Session II, May 11, 15:30-18:00, Foyer 42 CIMT Abstracts FZI Research Center for Immunotherapy Therapeutic Vaccination Abstract List (001 - 019) No.: Presenter: WHAT IS THE FZI? 001 Variation Allagui- The Research Center for Immunotherapy (FZI) is one of the major focus areas of biomedical research within the Johannes Gutenberg University in Mainz. It is located mostly on the medical campus and is composed of almost 50 research groups. With a dedicated research building, several core facilities, regular lecture series and a structured graduate and postgraduate training program, the vision of the FZI is to be one of Germany‘s prime locations for immunology research. 002 Angerer- Blood 003 Aurisicchio-Epitope-minigenes 004 Baert- Dendritic 005 Banki- Combination 006 Bialkowski-Intralymphatic 007 Bigalke- WT-1 008 009 Bulgarelli- The 010 Bunseyes Immune 011 Buonaguro-Discovery 012 Capasso- An 013 Cebulayes TLR9 014 Conner- Immune 015 016 Dal Col- Coding- 017 de Haar- Development 018 Deiser- Next-generation 019 Dewitte- Theranostic NEW AT THE FZI: The FZI represents outstanding third party projects on the way to an excellence center of immunological research in Germany: • TR SFB 156 „The skin as sensor and effector organ, orchestrating local and systemic immunity“ – together with Heidelberg and Tübingen • SPP 1937: „Innate Lymphoid Cells“ – coordinated by Prof. Dr. A. Diefenbach EVENTS CO-ORGANIZED BY THE FZI: FZI-SEMINAR SERIES 01. - 03.06.2016: 10th German Meeting on Immune Regulation, BerlinSchmöckwitz, Germany 27. - 28.06.2016: 19th T-Cell Meeting- Subsets and Functions, Marburg, Germany 04. - 07.07.2016: 1st Frankfurt Conference on Ubiquitin and Autophagy, Frankfurt/Main, Germany 20.11. – 02.12.2016: EMBO conference “Innate lymphoid cells – 2016”, Berlin, Germany 02.06.2016, 17.15: Wolfgang Weninger 16.06.2016, 17:15: Daniel Saban 07.07.2016, 17:15: Jonathan Kipnis 08.09.2016, 17:15: Hans-Reimer Rodewald 17.11.2016, 17:30: Mihai Netea 15.12.2016, 17:30: Bernard Malissen (UMC Mainz, building 706, lecture hall): UNIVERSITY MEDICAL CENTER of the Johannes Gutenberg University Mainz, Research Centre for Immunotherapy (FZI), Obere Zahlbacherstr. 67 , Building 905, D-55131 Mainz, Phone: +49 6131 178114 www.fzi.uni-mainz.de Shor t talk: Title: in susceptibility for human malignant melanomas to oncolytic measles virus DC preparations generated using automated CliniMACS Prodigy CD1c/CD304 enrichment and activation System efficiently activate CD8+ antigen-specific T-cells for optimal induction of the immune response against tumor associated antigens cell immunotherapy in ovarian cancer: an immunosuppressive challenge of oncolytic virotherapy and DC-based immunotherapy for the treatment of melanoma mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumors and PRAME mRNA transfected TLR 7/8 polarized fast DCs can raise specific immune responses in AML patients that correlate with clinical outcome - This abstract has been withdrawn double face of dendritic cell vaccination in metastatic melanoma: inducing intratumor immune response can switch tumor cells toward dedifferentiated state responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®) - HEPAVAC Epitope Discovery and Improvement System (EDIS) to study MHC-I epitopes and improve their sequences stimulation is required for recall of functional immune memory response against neo-antigen relapse in liver responses following intrapleural administration of the oncolytic HSV Seprehvir in patients with malignant pleural mesothelioma - This abstract has been withdrawn and non coding-RNA profiling of active dendritic cells following stimulation with highly immunogenic tumor cell lysates of a GMP production protocol for a cord blood-derived dendritic cell-based vaccine to prevent relapses after hematopoietic cell transplantation in children with AML dendritic cell vaccination in postremission therapy of AML: results of a clinical phase I trial mRNA-loaded microbubbles for ultrasound-assisted dendritic cell based cancer vaccination 45 CIMT Abstracts CIMT Abstracts Therapeutic Vaccination Therapeutic Vaccination Abstract List (020 - 038) Abstract List (039 - 057) No.: Presenter: 020 MERIT: Dorer- 021 Dörrie- A phase 022 023 Shor t talk: Title: No.: Presenter: Individualized cancer vaccines for the treatment of TNBC – a phase I trial 039 Design Kramer- I/II clinical trial on malignant melanoma with in vitro optimized mRNAelectroporated dendritic cells as therapeutic vaccine 040 Kuttruff-Coqui- 041 Kyzirakos- A 042 Lichty- Oncolytic 043 Löffleryes Personalized Eyrich- Dendritic cell vaccination with partial Treg depletion in relapsed glioblastoma – results from the pilot phase of the HIT-HGG Rez Immunvac study Eyrich- Characterization of TLR3/8-PGE2 versus TNFα/IL-1ß matured dendritic cells produced for clinical vaccination trials: impact of maturation on migration and T-cell priming/crosspresentation capacities Title: of reversible antigen-adjuvant conjugates for triggered release inside antigen-presenting cells GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma pipeline for fast track identification of candidate neoantigens from cancer exome sequencing data viral immunotherapy of HPV+ cancer multi-peptide vaccination induces immune responses associated with long term survival in a patient with metastatic intrahepatic cholangiocarcinoma 024 Feger- ORFV 025 Fotaki- Allogeneic 044 Lybaert- Innovative 026 Frøsig- The Ellegaard Göttingen minipig as a large animal model for anti-cancer vaccination 045 Mazorrayes Immunological 027 Gaudernack- UV1 – a second-generation, peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT) 046 Mikyšková-Cancer 047 Milleryes IVAC® 048 Moiseyes Improved 049 Montico- Exploiting 050 Mottas- Mixed 051 Müller- The 052 Nair- Oncolytic 053 Nelde- Identification 054 Orlinger- Development 028 Vector Vaccines – therapeutic potency in robust CRPV rabbit tumor model Shor t talk: dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as adjuvant for cancer immunotherapy Gerer- Immunotherapy of the Merkel Cell Carcinoma by vaccination with optimized DCs transfected with the viral oncogenic driver – the large T antigen 029 Grees- Development 030 Grenov- Developing of dendritic cell vaccination for combined melanoma immunotherapy a cancer vaccine for two-dimensional T cell activation using the Invari- ant chain Flt3L-based in situ vaccination for the treatment of lymphoma 031 Hammerich- 032 Haradayes A novel 033 034 035 combination immunotherapy consisting of tumor-associated macrophagetargeted vaccine, TLR agonist, and neoantigen-specific T cell transfer cures tumor highly resistant to immune checkpoint blockade Heidenreich- RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile Høgset- Photochemical internalization – light-induced enhancement of MHC Class I antigen presentation, giving strong enhancement of cytotoxic T-cell responses to vaccination Holmberg-Peptide vaccination against cancer testis antigens in combination with hypomethylating treatment for patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: An ongoing phase I study results obtained in castration-resistant prostate cancer patients treated with an EGFR-based vaccine. immunotherapy using dendritic cells pulsed with tumor cells killed by high hydrostatic pressure in murine models for prostate cancer MUTANOME – a first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma mutanome-directed cancer immunotherapy by immunoinformatic analysis of cancer neo-epitopes for regulatory T cell activation potential immunogenic cell death features for improved dendritic cell-based therapeutic vaccine against mantle cell lymphoma ligand coated gold nanoparticles as carrier of R848 for cancer immunotherapy mechanism of immune stimulation by Orf virus – a novel viral vector for therapeutic cancer vaccines poliovirus activates antigen-presenting cells and promotes anti-cancer responses in vitro and in vivo and characterization of HLA class I-restricted MYD88 L265P-derived peptides as tumor-specific targets for immunotherapy of novel replication-defective lymphocytic choriomeningitis virus vectors expressing HPV-16 antigens for immunotherapy 036 Hooijberg- Extent 055 Peres- Polymeric 037 Hoyer- BRAF 056 Podola- A phase 038 Jabulowsky- A 057 Podrazil- Immunological 46 and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant Active Specific Immunotherapy generic strategies for the encapsulation of patient-specific cancer antigens into immune-modulating particles and MEK inhibitors influence human immune cell phenotype and function first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients nanoparticle-based vaccine to target dendritic cells and the tumor microenvironment 2a trial and related preclinical studies to investigate the immunologic impact, anti-tumor efficacy and safety of VXM01, an oral T-cell inducing vaccine, in late stage colorectal cancer patients parameters in phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) in patients with rising PSA after primary prostatectomy or salvage radiotherapy for prostate cancer 47 CIMT Abstracts CIMT Abstracts Therapeutic Vaccination Cellular Therapy Abstract List (058 - 074) Abstract List (075 - 093) No.: Presenter: Shor t talk: Title: 058 iVacALL: Rabsteyn- A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants 059 Rabu- Optimizing synthetic long peptide-based anti-tumor vaccination using protease sensitive linkers 060 Ramachandran- Preclinical evaluation of triple microRNA-attenuated oncolytic Semliki forest virus in glioma and neuroblastoma 061 Rammensee- A new synthetic lipopeptide is a superior adjuvant for peptide vaccination 062 This abstract has been withdrawn 063 Rothe- Enhancing 064 Sainz- Promising - dendritic cell-induced T-cell responses by immunomodulating agents melanoma therapeutic cancer vaccine based on hybrid lipid-polymeric nanoparticles 065 Sanders- Xenogeneic 066 Schütz- Immunomodulatory 068 Shor t talk: 075 Identifying Allard- 076 Amann- Targeting capacity of CD47 functionalized artificial antigen-presenting combination of vasculature disrupting agent with TLR7/8 agonist: Promising strategy for melanoma therapy pseudotyped oncolytic vesicular stomatitis virus for the treatment of prostate cancer 077 Audehm- Comparison 078 Berger- Generation 079 Bianchi- Development 080 Bonte- Functional 081 Brey- Targeting 082 Campillo-Davo- RNAi-mediated silencing of endogenous TCR enhances tumor killing activity of TCR-engineered WT1 peptide-specific CD8+ T cells 083 Cappuzzello- Enhancing Cytokine-Induced Killer cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives 084 Chaperot- Potential 070 Van der Jeught- innate immune effector cell recruitment by interleukin-15 dendritic cells 085 Cripe- Seprehvir, Type I IFN induced upon particle mediated intravenous delivery of antigen mRNA enhances specific immune responses 086 Dutoit- MET-specific CARs for cell therapy of patients with GBM 071 Verbeke- Messenger RNA DOTAP-Cholesterol lipoplexes containing TLR agonists allow single step antigen-loading and maturation of dendritic cells 087 Fåne- Development of novel chimeric antigen receptors (CAR) to treat B-cell malignancies 072 Vormehr- Neo-epitopes 073 Wollmann-LCMV-GP 074 Yangyes Immunotherapy generated by insertions, deletions and gene fusions as targets for personalized tumor vaccination 088 Friese- Constructing pseudotyped oncolytic vesicular stomatitis virus for the treatment of ovarian cancer 089 Gary- Insights with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in Human Papillomavirus (HPV) associated Head and Neck Squamous Cell Carcinoma (HNSCCa): Interim results 090 Gomez-Eerlandyes 091 Hillerdal- Characterization 092 Hodgins- Liposomes 093 Inderberg- Adoptive rare, high avidity self/tumor-specific CD8 T cells in cancer patients of two allorestricted T-cell receptors targeting two different Myeloperoxidase-derived HLA-B*07:02-restricted peptide epitopes with different MHC affinities with respect for their therapeutic potential of chimeric antigen receptor - modified memory stem cell CD8+ T lymphocytes from naive precursors by modulation of Wnt/ß-catenin pathway or inhibition of Akt-signaling of imaging strategies for investigation of TCR with defined antitumor reactivity in vivo evaluation of tumor antigen specific T-cells generated from TCR transduced human hematopoietic stem cells Urbiola- LCMV-GP Van Acker-Superior Title: simultaneously non-mutated HLA.A2-restricted MDM2 and p53 tumorassociated antigens as a novel double-edged swords approach for TCR gene therapy for multiple myeloma Seth- Synergistic 069 48 Presenter: vascular endothelial growth factor-2 vaccination in tumor bearing mice cells (aAPCCD47+) 067 No.: HCMV-infected fibroblasts with bi-specific CAR-T cells immunogenicity of PUVA-induced cell death an oncolytic herpes immunotherapeutic, enhances GD2-directed Chimeric Antigen Receptor (CAR) T-cell therapy in GD2-expressing solid tumor xenografts artificial antigen-presenting cells for improved T-cell function in adoptive T-cell therapy of melanoma into the preventive/preemptive adoptive transfer of CMV- and EBV-specific peptide-stimulated T cells after allogeneic stem cell transplantation as part of the phase I/IIa clinical trial MULTIVIR-01 Adoptive transfer of autologous T cells modified with a MART-1 specific TCR in advanced stage melanoma patients of the avidity of TCR-engineered T cells with novel and established approaches encapsulating zoledronic acid for cancer immunotherapy and their effect on the in vivo biodistribution of Vg9/Vd2 T cells in different tumour models immunotherapy with a little help from CD4 T cells 49 CIMT Abstracts CIMT Abstracts Cellular Therapy Cellular Therapy Abstract List (094 - 112) Abstract List (113 - 132) No.: Presenter: vitro stimulation conditions affect the immune phenotype of both CD4+ and CD8+ T cells expressing a GD2-specific chimeric antigen receptor 113 Exploiting Owens- recovery of innate immune cells after αβ T-cell depleted allogeneic stem cell transplantation from matched related and unrelated donors 114 Pfeifferyes Towards 115 Raemdonck- Exploring novel siRNA delivery approaches with cytotoxic T cells 116 This abstract has been withdrawn Kayser- CD4+ 117 Rataj- Arming 098 Kirkin- Development 118 Sandri- Feasibility 099 Klaver- Plasma 119 Schaft- Receptor-transfected 120 Schooryes On- No.: Presenter: Shor t talk: Title: 094 In Jamitzky- 095 Janssen- Rapid 096 Jin- Safe engineering 097 of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer T-helper-1 cells against the tumor antigens WT1, NY-ESO-1, ROR1, MAGE-A3 and Survivin for adoptive transfer to treat cancer of multi-groove tissue culture flasks for growing of lymphocytes used in adoptive immunotherapy IFNγ and IL-6 levels correlate with peripheral T-cell numbers in RCC patients treated with CAR T-cells Shor t talk: Title: tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in ovarian cancer – a proof of concept study - in vivo delivery of chimeric antigen receptors T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells of telomerase-specific adoptive T-cell therapy for hematologic and solid malignancies and off target toxicity profiling for adoptive cell therapy by mass spectrometrybased immunopeptidome analysis of primary human normal tissues 100 Kraus- Functional 101 Kremer- CXCR2 121 Schörgyes Combining 102 Kunert- TCRs 122 Schütt- Two 123 Schütz- Nanoparticle 103 Kunert- Intra-tumoral 124 Simonyes Retrieval 104 Lameris- Activation 125 Singhyes Novel 105 Legscha- Targeting 126 Solum- Serum 106 MacLeod- Integration 127 107 Mall- Mapping 128 Such- Characterization 108 McCreedyyesAllogeneic 129 Taborska- Human 109 Mensali- Csk 130 Tosi- Identification 110 Mroz- Individualized 131 Tubb- Targeting 132 Uslu- Generating for MAGE-C2, in combination with epigenetic drug treatment of target cells, yield tumor-selective therapeutic T cells production of IL18, but not IL12, by ‘smart’ T cells is non-toxic and counteracts immune evasion of solid tumors, prolonging survival of invariant natural killer T-cells by a unique anti-CD1d single domain antibody induces potent tumor destruction in vitro tumor suppressor p53 isoforms as a novel approach to improve T-cell based immunotherapy of a CD19 CAR gene into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells of T-cell receptor-engineered human T cells at the tumor site by Immuno-PET CAR-T cells gene edited to insert an anti-CD19 CAR into the TCR alpha locus target and kill CD19+ Raji lymphoma tumors in vitro and in vivo without causing GvHD overexpression makes T cell dummy immunotherapy of ovarian cancer by targeting Claudin-6 with CARengineered T cells 111 Oberoi- Generation 112 50 characterization of different variants of a PD-1-CD28-fusion receptor chemokine receptor transduction of human NK cells to improve migration to solid tumors of tumor-specific NK cells by differentiation of CAR-gene transduced hematopoietic progenitors - This abstract has been withdrawn γ/δ T cells; the new magic bullets against melanoma? tumor antigen (TA) specific Th1 cells with immune checkpoint blocking antibodies induces tumor regression in advanced carcinomas are better than one?! Improving safety for CAR T cell therapy based antigen-specific redirection of T cells to tumors of functional TCRs from single neo-antigen-specific T cells: Toward individualized TCR-engineered therapies immunotherapies for recurrent glioblastoma: The efficacy of CD133 BiTEs and CAR T cells in preclinical models replacement might substitute human serum in the GMP production of Dendritic Cells - This abstract has been withdrawn of recognition profiles of TCRs by a novel DNA-barcode based multiplex technology dendritic cells pulsed with high hydrostatic pressure-inactivated prostate cancer cells and matured with poly(I:C) induce autologous lymphocytes to ex vivo recognize and kill prostate cancer cells of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1 of recurrent somatic cancer mutations for T cell receptor gene therapy T cells expressing two additional receptors (TETARs) by combining a chimeric antigen receptor and a conventional T-cell receptor for multi-hit cancer immunotherapy 51 CIMT Abstracts CIMT Abstracts Cellular Therapy Immunomonitoring Abstract List (133 - 138) Abstract List (139 - 157) No.: Presenter: Shor t talk: Title: 133 A novel Voss- 134 Wälchli- A universal 135 Weinstein-Marom- stabilized single chain TCR format allows for the generation of virus/tumor antigen-bispecific human T-cells and prevents mispairing with endogenous TCRs killer T-cell for adoptive cell therapy of cancer Enhancing the effector functions of T cells with a combination of new mRNA adjuvants for improving adoptive cell therapy 136 Wennhold-Tumorantigen-Specific 137 Westergaard- 138 No.: Presenter: Shor t talk: 139 Massive Andersen- 140 Bentzenyes Next-generation 141 Challis- CIP 142 Chandran- Automated 143 Chiang- Radiation-expanded 144 Coosemans- 145 de Goeje- Immune 146 de KoningyesCD4+ 147 Galaine- Immunoprevalence 148 Gouttefangeas- 149 Krebs- Evaluation multiplexing: DNA barcode Dextramers for T cell epitope discovery and epitope profiling detection of cancer-responsive T cells using DNA barcode-labeled peptide-Major Histocompatibility Complex I multimers NK proficiency panel 2016: Reducing inter-lab variation in NK activation and functional markers, CIP CD40-activated B cells for cancer immunotherapy Preclinical development of Tumor-Infiltrating Lymphocytes (TILs) based Adoptive Cell Transfer Immunotherapy (ACT) for patients with advanced ovarian cancer NK cells display potent activity against glioblastoma and induce protective antitumor immunity Title: flow cytometry analysis by ReFlow myeloid-derived suppressor cells are responsible for local failure of radiation therapy Zhang- Targeted Preliminary results of a prospective immunomonitoring trial in ovarian cancer patients monitoring of lung cancer patients to predict clinical outcome using an automated pipeline for flow cytometry data analysis T-cell immunomonitoring after hematopoietic cell transplantation: identifying patients at risk for virus-predicted adverse outcomes and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 Th1 responses against telomerase in cancer patients Immunomonitoring and immunoguiding: update on the CIP activities, CIP of novel predictive marker molecules in malignant melanoma immuno- therapy 150 Lyngaa- Type, frequency and breadth of tumor associated antigen reactivity in tumor infiltrating lymphocyte from metastatic melanoma patients 151 Mandruzzato- Results from the first phase of a harmonization effort for the phenotyping of human myeloid-derived suppressor cells, CIP 152 Niedermannyes Noninvasive ImmunoPET imaging of the PD-1/PD-L1 checkpoint in naïve and irradiated tumor-bearing mice 153 Omokoko- NGS-based 154 Peper- Peptide-specific αβTCR repertoire analysis in tumor and blood from three melanoma patients pre and post IVAC® MUTANOME vaccination T-cell responses against tumor-specific HLA ligands in ovarian cancer 52 155 Rathinasamy- Tumor antigen specific Treg from the bone marrow migrate towards increased S1P and CCL2 gradients established in the blood of breast cancer patients 156 Rodrigues-Santosyes Immune monitoring of natural killer cells in chronic myeloid leukemia: split anergy status depend on tyrosine kinase inhibitor therapy 157 Schmidtyes Isolation and analysis of tumor-specific CD8 and CD4 T cells with high affinity, reversible pMHC multimers 53 CIMT Abstracts CIMT Abstracts Immunomonitoring New Targets & New Leads Abstract List (158 - 166) Abstract List (167 - 186) No.: Presenter: 158 PD-1 Simon- 159 Stam- Systemic 160 Shor t talk: Title: blockade induces quantitative and qualitative changes within a vast and common antigen-specific T cell repertoire in melanoma treated patients WT-1 specific T cell reactivity in relation to immune status and survival following ablative treatment of locally advanced pancreatic cancer by irreversible electroporation Tudor- An optimized IFN-γ ELISpot assay to determine CMV protein-reactive effector cells of cell- mediated immunity 161 Turksma- Antigen-specific T cell immunomonitoring by HLA tetramer combinatorial coding for CD8 T cells and CD40L expression on antigen-specific CD4 T cells 162 Vigano- Clinical 163 Welters- Detection 164 Welters- A kit 165 Wistuba-Hamprecht- Associations of peripheral blood Vδ1+ γδ T-cells with overall survival of melanoma patients 166 Zelle-Rieser- Bone marrow T cells from myeloma patients exhibit features of both T-cell exhaustion and senescence immunomonitoring strategies assessing on-target and off-target effects of anti-CD73 mAbs - The TumAdoR collaborative project and functional assessment of regulatory T cells in clinical samples, CIP for the preparation of T-cell Receptor Engineered Reference Sample (TERS) to control T-cell assay performance, CIP No.: Presenter: Shor t talk: Title: 167 Identifying Ashfield- 168 Ayersyes Relationship 169 Bassani-Sternbergyes 170 Beck- Validation tumour-specific Class I MHC peptide epitopes by Mass Spectrometry between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab in patients with advanced solid tumors Direct identification of neo-epitopes using in-depth immunopeptidomics of melanoma tissues for the development of anti-tumor immunotherapies of a clinical 1400-gene assay for genomic profiling of cancer from DNA and RNA cancer therapies – a role for cold physical plasma against pancreatic malignancies in vitro and in vivo 171 Bekeschus-ROS-based 172 Braitbard- Signal 173 Bräunlein 174 Buettner- The 175 Charpentier- Within the family of MELOE antigens, IRES-dependent translation conditions exclusive expression in melanoma cells and immunogenicity 176 Deumelandt- Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells 177 Di Marco- A 178 Doorduijn- A 179 Doorduijn- TAP-independent peptide derived monoclonal antibodies impair mmtv-associated tumor growth - Immunogenicity assessment of mutated HLA-ligands identified on melanoma tissue probes by mass spectrometry HLA-associated phosphoproteome as a new target for immunotherapy against hepatocellular carcinoma “multi-omics approach” for the identification of T cell epitopes in clear cell renal cell carcinoma novel role for CD4+ T cells in clearance of highly aggressive MHC-I low tumors mediated via NK cells self-peptides enhance T cell recognition of immune-escaped tumors 54 Genetic engineering using CRISPR/Cas9: Targeting MMP23 in melanoma 180 Halldórsdóttir- 181 Ileckayes Antigen-armed 182 Kedde- A novel 183 Krächan- A novel 184 - This abstract has been withdrawn 185 KreuzbergyesIMAB027-DM1 186 Kwekkeboom- antibodies in the treatment of B-cell lymphoma highly tumor-specific antibody for acute myeloid leukemia and myelodysplastic syndrome targeting a sialylated epitope of CD43 TLR7 agonist reverses NK cell anergy and cures lymphoma-bearing mice and IMAB027-vcMMAE, CLDN6-specific antibody-drug conjugates, are effective against human CLDN6-positive cancer cells in vitro and in vivo Tumor expression of immune inhibitory molecules and TIL counts predict pancreatic cancer survival 55 CIMT Abstracts CIMT Abstracts New Targets & New Leads New Targets & New Leads Abstract List (187 - 205) Abstract List (206 - 215) No.: Presenter: Shor t talk: Title: 187 Targeting Lee- 188 Leon- Human 189 Leon- Blocking 190 Marillier- PF-06840003: 191 192 of reactive oxygen species can be a potential therapeutic strategy for cancer treatment IL-2 agonist exhibits a higher antitumor efficacy and lower toxicity than wild type IL-2 in different preclinical contexts IL-2 signal in vivo with IL-2 antagonist reduces tumour growth through the control of regulatory T cell accumulation No.: Presenter: Shor t talk: Title: 206 The Schuster- 207 Schwenck-Clinical 208 Shuttleworth- KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110β/ p110δ and HDAC6 with single-agent and combination activity This abstract has been withdrawn immunopeptidomic landscape of ovarian carcinoma non invasive in vivo imaging of the differentially expressed tumor associated antigen PSMA by a specific Positron Emission Tomography (PET) ligand 209 a highly selective IDO1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors, and favorable predicted human pharmacokinetic properties 210 Suarez-Carmona- This abstract has been withdrawn 211 Thierauf- Checkpoint-Inhibition Marschall-Protecting 212 Trezise- Quantitative 193 Menevse- Discovering 213 van Helden- Rapid 194 Michels- TiMi1 is a novel immune checkpoint in solid tumors differentially regulating cAMP-depending signaling in tumor-infiltrating lymphocytes 214 Walter- Anti-tumor 195 Mitnacht-Kraus- IMAB362-vcMMAE , a CLDN18.2-specific antibody-drug conjugate, is effective against human gastric cancer cells in vitro and in vivo 215 Zelba- In renal 196 Okadayes Novel 197 Olwill- Costimulatory 198 Paret- Immunogenic 199 Pfeiferyes Sialyl 200 Platzer- Cytoreductive 201 Posselt- Targeting - immune cells from activation-induced apoptosis via the CD95L-blocking compound APG101 novel targets in a high-throughput fashion: RNAi screen for pancreatic ductal adenocarcinoma (PDAC) associated immune modulators - Ovarian carcinoma explant culture: model development and application in drug testing for advanced mucosal melanoma live-cell imaging assays for immunotherapy: chemotaxis, T-cell killing & phagocytosis generation of T cell receptor like antibodies using genetically reprogrammed memory B cells of immunized rabbits activity of IMAB027 antibody as a single agent and in combination with chemotherapy in testicular cancer cell and prostate cancer a large fraction of the tumor-infiltrated T-cells cannot be targeted by current checkpoint inhibition approaches and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation T-cell engagement by the CD137/HER2 bispecific, PRS-343, leads to anti-tumor effect and increased tumor infiltrating lymphocytes in a humanized mouse model lipids of pediatric brain cancer Glycolipid Stage-Specific Embryonic Antigen 4 (SSEA4) – a novel target for CAR T cell therapy of solid cancers and Immunmodulatory drugs influence bispecific CD33/CD3 BiTE® antibody construct (AMG 330) mediated cytotoxicity against Acute Myeloid Leukemia (AML) DNA damage response genes to improve radiotherapy of pancreatic can- cer 202 Ramskov- Evaluating 203 Riemer- Evaluation 204 Ruzicka- Immunotherapy 205 Schnieders-4-1BBL 56 prediction strategies for identification of immunogenic mutation-derived neo-epitopes in melanoma of T cell epitope prediction servers targeting RIG-I in a mouse model of acute myeloid leukemia synergizes with IL-12 and IL-2 in the induction of a defensive immune signature in the human urinary bladder carcinoma microenvironment 57 CIMT Abstracts CIMT Abstracts Improving Immunity Improving Immunity Abstract List (216 - 233) Abstract List (234 - 244) No.: Presenter: Shor t talk: Title: No.: Presenter: 216 Second Beha- 217 Bou Nasser Eddine- 218 Buonaguro-Effects 219 Clemenz- Dermaject generation of IL-15-based tri-functional antibody fusion proteins with costimulatory TNF-superfamily ligands for cancer therapy 234 Parviainen-TNFa Optimal triggering of anti-tumor CD4+ TH cells by tumor cells expressing CIITAdriven MHC class II I-A-only molecules 235 Rekdal- The of RNA-based RNAdjuvant® on PBMCs from liver cancer patients in an ex vivo model 236 Richardsyes Hexavalent 237 Sanders- Immunological, 238 Sapski- Combinatorial 239 Spagnuolo-Modulation – a novel, convenient intradermal injection device for intracutaneous Shor t talk: and IL-2 armed oncolytic adenovirus induces antitumor immune response and protects from tumor rechallenge in Syrian hamsters oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with CTLA-4 blockade agonists targeting receptors of the tumor necrosis factor superfamily: TRAIL, CD40L, CD27L and beyond anti-angiogenic and clinical effects of intratumoral interleukin-12 electrogene therapy plus metronomic cyclophosphamide in dogs with spontaneous cancer injections 220 221 checkpoint blockade enhances anti-tumor activity of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors ColombettiyesPD-L1 an oncolytic herpes viroimmunotherapeutic, enhances therapeutic efficacy of T cell checkpoint inhibition in solid tumors by increasing T cell recruitment and remodeling the immunosuppressive microenvironment approaches with costimulatory antibody fusion proteins addressing immunosuppression by IL-10, TGF-beta and immune checkpoints Cripeyes Seprehvir, 222 de Gruijlyes Local adjuvant treatment of clinical stage I-II melanoma with CpG-B/GM-CSF improves distant recurrence-free survival: long-term follow-up of three randomized controlled phase II trials 223 Donnellan-IMCgp100 224 Eissleryes Release 225 Holland- Comparison 226 Hotz- Reprogramming ImmTAC: A TCR-based bi-specific immunotherapy for the treatment of advanced melanoma of IFN-γ induced chemokines provides the key to efficient combination immunotherapy of anti-PD-1 antibody with CSF-1R inhibitor of phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies of TLR7 signaling enhances antitumor NK and cytotoxic T cell Title: of T cell recruitment into tumors through synergy between HMGB1 and CXCL12 Efficacy of a novel multi-drug metronomic chemotherapy combined with a peptide vaccine on tumor challenge in mice 240 Tagliamonte- 241 Tähtinen- T-cell 242 Theurich- Local 243 Tognarelli-NK 244 Zhu- Combination therapy enabling adenoviruses coding for IL-2 and TNF-a systematically activate tumor-reactive TILs in metastatic, solid cancer tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma cell characteristics and anti-tumor efficacy in multiple myeloma and lymphoma patients before and after autologous stem cell transplantation immunotherapy of an inducible, autochthonous, low mutational load murine lung cancer model expressing human CEA as a tumor-associated self-antigen responses 227 Kapp- In vitro and in vivo evaluation of the TLR9 agonist EnanDIM for cancer immuno- therapy 228 Kayali- Platelet-derived 229 Kikodze- Influence 230 Koksal- Memory-like 231 Kwekkeboomyes Functionality of tumor-infiltrating T cells in hepatocellular carcinoma can be enhanced by blocking several co-inhibitory pathways 232 Kwekkeboom- Blocking PD-L1 and LAG-3 can revitalize the functionality of tumor-infiltrating T cells in liver metastasis from colorectal cancer 233 O'Donnell- Probing 58 microparticles differentially regulates macrophage polarization of radiofrequency thermal ablation on CD4+ T cell subsets in the patients with liver cancer T cells transduced with tumor-specific epitope elicited pronounced cytotoxic potential the increase in neoantigen burden at recurrence in ovarian cancer 59 CIMT Abstracts CIMT Abstracts Tumor Biology and Interaction with the Immune System Tumor Biology and Interaction with the Immune System Abstract List (245 - 263) Abstract List (264 - 281) No.: Presenter: 245 TRPV1 Akman- 246 Al Absi- Actin 247 248 249 250 Shor t talk: Title: and TrkA agonists alter cytokine secretions of mix leukocyte cultures obtained from tumor-bearing mice cytoskeleton remodeling: a novel mechanism for tumor cells to escape from natural killer cell-mediated cell death tolerance transforms tumor antigen specific naive CD4 T cells into induced Tregs in a spontaneous lung tumor model No.: Presenter: 264 The effects Erin- 265 Erin- Inhibition 266 Erin- Effects 267 Fernandes-Characterization Alonsoyes "Infectious" Arakelian- Hypoxia in the tumor microenvironment: A major regulator of the anti-tumor immune response macrophage phenotype makes low grade ovarian cancer a possible target for immunotherapy of PKC activity with Byrostatin alters secretion of inflammatory chemokines of phosphoramidon on TNF-a and IFN-g release from mix leukocyte culture obtained from tumor-bearing mice of the immunogenicity of pancreatic cells in response to electro- Fischer- Tumor-infiltrating 269 Fischer- Bifunctional 270 Foerster- The 271 Foerster- Allogeneic 272 Forlani- Block 273 Furnessyes Characterisation role of local immune infiltrate in patients with colon cancer 274 Gabriele- On-chip of MHC class I and class II deficient tumor cell lines using the CRISPR/ Cas9 system 275 Georganaki- Sunitinib 276 Gorris- Development 277 Hassel- Investigation 278 Hu- Role of 279 Kienzle- Targeting 280 Kim- A novel 281 Knott- Tumor-derived Berthel- Spatial heterogeneity of T cell distribution patterns at the invasive margin of colorectal cancer liver metastases T cell costimulatory pathways are required for cisplatin-based chemotherapy 252 Bjerregaard- MuPeXI: A tool for prediction of neo-epitopes from tumor sequencing data 253 Blattner- The 254 Boegel- Determination 255 Buoncervello- 256 Calvo- Prognostic 257 Das- Generation role of CCR5 on MDSC in their recruitment and activation in melanoma microenvironment of HLA type and expression from whole transcriptome sequencing data (RNA-Seq) IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer 258 de Bruyn- Treatment 259 Dekenyes Synergy regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer of anti-PD-1 in combination with targeted therapy is mediated by CD8+ T cells 260 Dosset- PD-L1 261 Eggink- POLE 60 of PU-H71, a novel HSP90 inhibitor, and radiotherapy co-treatment in metastatic breast carcinoma: Changes in IL-6 and macrophage inflammatory protein 2 268 Beyranvand Nejad- 263 Title: chemotherapy Baert- Tumour-associated 251 262 Shor t talk: tumor expression as an adaptive immune resistance mechanism to counter the antitumor effect of immunogenic chemotherapies proofreading domain mutations elicit an antitumor immune response in endometrial cancer Elkord- GARP/LAP expression on FoxP3+/-Helios+/- Treg subsets in patients with pancreatic cancer and liver metastases from colorectal cancer Erin- CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carcinoma: Possible role of in-vivo increased anti-tumoral immune response B lymphocytes independently predict outcome in patients with non-small cell lung cancer and consist mostly of effector subsets peptide-MHC class I antibody fusions redirect peptide-specific CD8+ T cells to eliminate tumor cells in vivo immunome of hepatocellular carcinoma – an in silico analysis Balb/c mice are more susceptible to B16F10 liver metastasis than syngeneic C57/Bl6 mice despite a M1-polarized anti-tumor immune response of the HTLV-1 Tax-1 oncogene-dependent NF-kB activation by the MHC class II transactivator CIITA. Implications for the control of oncogenic potential of HTLV1 infection of immune and tumour-specific neoantigen landscapes informs optimal therapeutic targeting in non-small cell lung cancer dialogue between immune cells and cancer: tracking human dendritic cell migration and tumor antigen capture upon drug treatment enhances the anti-tumor responses of agonistic CD40-antibody therapy by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment of multiplex fluorescent IHC immune cell panels to predict immunotherapy outcome of tumor-reactive T-cell repertoire in the immune infiltrate of metastatic melanoma under immune checkpoint inhibition tumor-derived exosomes in immunosuppression in malignant melanoma Cancer: Encapsulation of TNF-α in pH-sensitive PEI-PEG copolymer gated dendritic mesoporous silica nanoparticle model of murine hepatocarcinogenesis in biliary fibrotic mice resembling the multistage process of human primary liver cancer IL-1 mediates intratumoral immunosuppression via the Treg-attracting chemokine CCL22 61 CIMT Abstracts CIMT Abstracts Tumor Biology and Interaction with the Immune System Tumor Biology and Interaction with the Immune System Abstract List (282 - 300) Abstract List (301 - 319) No.: Presenter: 282 Shor t talk: Title: No.: Presenter: Escape Koch- 301 Increased Qureshi- 283 Komdeur- CD103 302 Ramjiawanyescxcr4 284 Konkol- Presence of immune infiltrates in early phases of prostate cancer: Development of a preclinical efficacy model to promote immunotherapy development 303 Röhle- Characterization PD-L1, Galectin-9 and CD8+ TIL are associated with patient survival in Hepatocellular Carcinoma 304 Sainiyes Identification vivo high-throughput T cell receptor profiling of a melanoma patient’s peripheral tumor antigen-specific T cell repertoire 305 Sapega- IL-12 Patient-derived tumor xenografts in humanized NSG and NSG-SGM3 mice: A model to study immune responses in cancer therapy 306 Sauer- HLA 307 Schmidt- Tumor 308 Schotte- A patient of head and neck squamous cell carcinoma from NKG2D-dependent NK cell immunosurveillance can be restored by NKG2D ligand depletion defines intraepithelial CD8+ PD1+ tumor-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma Shor t talk: Title: CD4+ and CD8+ lymphocytic infiltration in patients with triple negative breast cancer suggests susceptibility to immune therapy inhibition in tumor microenvironment facilitates anti-program death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice and characterization of neoepitopes associated with individual mutational landscape in non-small cell lung cancer 285 Kwekkeboom- 286 Lennerz- Ex 287 Low-Marchelli- 288 Marcq- Into 289 Metzger- Surface 290 Momose- Identification 309 Schrörs- Complex 291 Mullins- A Crohn´s related colonic carcinoma cell line showing features of immunoselection is recognized by re-activated autologous tumor-infiltrating lymphocytes as well as CIK cells 310 Schupp- Activating 292 Nesmiyanov- mIRNA-155 shuttling through gap junctions facilitates CLL progression 311 Seo- The role 293 Ozdemir- Investigation 312 Shatnyeva-BAG6 313 Siozopoulou- the deep: closer look at immune cells and immune checkpoint expression in human malignant pleural mesothelioma staining of PD-1 discriminates viable cell populations of cytotoxic miRNAs in human T cell-released exosomes against mesenchymal stem cells of paracrine immunomodulatory effects of mesenchymal stem cells on the CD4+ T cell subsets The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G and HLA expressions in the advanced stage breast cancer therapy suppresses TC-1 tumor growth accelerated by admixture of the docetaxel-treated senescent tumor cells class II antigen expression in cervical intraepithelial neoplasia and invasive cancer and host cell PD-L1 expression is required to mediate suppression of antitumor immunity derived antibody targeting CD9 inhibits melanoma metastasis deletion event at B2M locus in a human melanoma patient treated with IVAC MUTANOME and repolarizing immune suppressive tumor associated macrophages using siRNA encapsulated in nano-sized carriers to initiate an anti-tumor immune response against melanoma of CD8+ T cell-released exosomes on the down-regulation of tumor invasion and metastasis by elimination of stromal mesenchymal cells and CBP/p300 regulate ESCRT-mediated exosomes release and protein sorting Desmoid tumors: the importance of the immune cell determination to the development of new treatment options 294 Özgül Özdemir- 295 Park- Evaluation 314 Skadborg- Characterization 296 Parri- Identifying 315 Solinas- Characterization 297 Parrot- CD40L+CD4+CD8+ 316 Sonner- No 317 Steinhoff- PD-L1 318 Stoitzner- Cooperation 319 Tanriover- The of potential factors contributing to immunosuppression in the PDL1 positive tumor microenvironment the kinases and phosphatases regulating STAT3 with potential dual anti-cancer and immunotherapeutic effects intra-tumor double positive T cells : a helper player in mela- noma 298 299 Prokopi- Immune 300 Qureshi- Characterization 62 - This abstract has been withdrawn evasion by melanoma: Modification of the skin and lymph node immune cell network in a spontaneous melanoma mouse model of the cancer immune microenvironment of Mdr2(Abcb4)-/- mice treated with Diethylnitrosamine and Phenobarbital – A novel model close to human Hepatocracinogenesis and specificity analysis of tumor infiltrating lymphocytes in ovar- ian carcinoma of inhibitory molecules on tumor-infiltrating lymphocytes in malignant melanoma of PD-L1 and PD-1 expression in tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients role of the stress kinase GCN2 in T cell-mediated tumor rejection as intratumoral tryptophan levels are maintained upregulation following RLR and TLR-based immunotherapy in a mouse model of gastric cancer of Langerhans cells and NK cells guarding the epidermis during chemical carcinogenesis expression of Gr1+ and S100A8/A9+ cells in primary tumors and visceral organs invaded by breast carcinoma cells 63 CIMT Abstracts CIMT Abstracts Tumor Biology and Interaction with the Immune System Abstract List (320 - 331) No.: Presenter: Shor t talk: Title: 320 Taranikanti- Alteration 321 ten Buren-Genetic 322 Thomé- Glioma 323 Treder- Anti-tumor of host immunity with stress in breast cancer patients engineering in a non-traditional astrocytoma prone mouse background N-Myc downstream regulated gene 1 (NDRG1) shapes the tumor microenvironment efficacy by the bispecific tetravalent CD30/CD16A TandAb AFM13 is characterized by strong cross-talk from innate to adaptive immunity and is enhanced by immune checkpoint inhibitor anti-PD-1 324 Vascotto- Induction of a well-defined immune response using a novel systemically applied Toll-Like Receptor 7 agonist in mice and men 325 VerdegaalyesA 326 Vetter- Tolerogenic 327 Voigt- Impact 328 Wölfl- A dual changing neo-antigen landscape in human melanoma under T cell pressure effects of GM-CSF through expansion of regulatory T-cells and induction of the Treg-associated chemokine CCL22 of Interleukin-22 on two murine models of lung and breast cancer role for IL12 in T-cell receptor-dependent and –independent tumor cell killing: regulation of a DNAM1 mediated, PTPRC/CD45-dependent mechanism in human effector T-cells Patient-derived tumor xenografts in humanized mice: a preclinical model for the development of innovative immunotherapeutics 329 Wulf-Goldenberg- 330 Zayoud- The 331 Zhao- Genetic role of the IL-22/IL-22R1 axis in Pancreatic ductal adenocarcinoma heterogeneity of intra-patient metastases restricts T-cell recognition of malignant melanoma [ A ] Akman. . . . . . . . . . . . . 245 Al Absi. . . . . . . . . . . . . 246 Allagui. . . . . . . . . . . . . 001 Allard. . . . . . . . . . . . . . 075 Alonso. . . . . . . . . . . . . 247 Amann. . . . . . . . . . . . . 076 Andersen. . . . . . . . . . 139 Angerer. . . . . . . . . . . . 002 Arakelian . . . . . . . . . . 248 Ashfield. . . . . . . . . . . . 167 Audehm . . . . . . . . . . . 077 Aurisicchio. . . . . . . . . 003 Ayers. . . . . . . . . . . . . . 168 [ B ] Baert. . . . . . . . . . . . . . 004 Baert. . . . . . . . . . . . . . 249 Banki. . . . . . . . . . . . . . 005 Bassani-Sternberg. 169 Beck. . . . . . . . . . . . . . . 170 Beha . . . . . . . . . . . . . . 216 Bekeschus. . . . . . . . . 171 Bentzen . . . . . . . . . . . 140 Berger. . . . . . . . . . . . . 078 Berthel . . . . . . . . . . . . 250 Beyranvand Nejad . . 251 Bialkowski. . . . . . . . . 006 Bianchi . . . . . . . . . . . . 079 Bigalke . . . . . . . . . . . . 007 Bjerregaard. . . . . . . . 252 Blattner. . . . . . . . . . . . 253 Boegel. . . . . . . . . . . . . 254 Bonte. . . . . . . . . . . . . . 080 Bou Nasser Eddine. . 217 Braitbard . . . . . . . . . . 172 Bräunlein. . . . . . . . . . 173 Brey. . . . . . . . . . . . . . . 081 Buettner. . . . . . . . . . . 174 Bulgarelli . . . . . . . . . . 009 Bunse . . . . . . . . . . . . . 010 Buonaguro. . . . . . . . . 011 Buonaguro. . . . . . . . . 218 Buoncervello. . . . . . . 255 [ C ] Calvo. . . . . . . . . . . . . . 256 Campillo-Davo. . . . . 082 Capasso. . . . . . . . . . . 012 Cappuzzello. . . . . . . . 083 Cebula. . . . . . . . . . . . . 013 Challis. . . . . . . . . . . . . 141 Chandran. . . . . . . . . . 142 Chaperot. . . . . . . . . . . 084 Charpentier. . . . . . . . 175 Chiang. . . . . . . . . . . . . 143 Clemenz. . . . . . . . . . . 219 Colombetti. . . . . . . . . 220 Conner. . . . . . . . . . . . . 014 Coosemans. . . . . . . . 144 Cripe. . . . . . . . . . . . . . . 085 Cripe. . . . . . . . . . . . . . . 221 [ D ] Dal Col. . . . . . . . . . . . . 016 Das. . . . . . . . . . . . . . . . 257 de Bruyn. . . . . . . . . . . 258 64 de Goeje. . . . . . . . . . . 145 de Gruijl. . . . . . . . . . . . 222 de Haar. . . . . . . . . . . . 017 de Koning. . . . . . . . . . 146 Deiser. . . . . . . . . . . . . 018 Deken . . . . . . . . . . . . . 259 Deumelandt . . . . . . . 176 Dewitte. . . . . . . . . . . . 019 Di Marco. . . . . . . . . . . 177 Donnellan. . . . . . . . . . 223 Doorduijn. . . . . . . . . . 178 Doorduijn. . . . . . . . . . 179 Dorer. . . . . . . . . . . . . . 020 Dörrie. . . . . . . . . . . . . . 021 Dosset. . . . . . . . . . . . . 260 Dutoit . . . . . . . . . . . . . 086 Hooijberg. . . . . . . . . . 036 Hotz. . . . . . . . . . . . . . . 226 Hoyer. . . . . . . . . . . . . . 037 Hu. . . . . . . . . . . . . . . . . 278 [ I ] Ilecka. . . . . . . . . . . . . . 181 Inderberg. . . . . . . . . . 093 [ J ] Jabulowsky . . . . . . . . 038 Jamitzky. . . . . . . . . . . 094 Janssen. . . . . . . . . . . . 095 Jin. . . . . . . . . . . . . . . . . 096 [ E ] Eggink. . . . . . . . . . . . . 261 Eissler. . . . . . . . . . . . . 224 Elkord . . . . . . . . . . . . . 262 Erin. . . . . . . . . . . . . . . . 263 Erin. . . . . . . . . . . . . . . . 264 Erin. . . . . . . . . . . . . . . . 265 Erin. . . . . . . . . . . . . . . . 266 Eyrich. . . . . . . . . . . . . . 022 Eyrich. . . . . . . . . . . . . . 023 [ F ] Fåne. . . . . . . . . . . . . . . 087 Feger. . . . . . . . . . . . . . 024 Fernandes. . . . . . . . . 267 Fischer . . . . . . . . . . . . 268 Fischer . . . . . . . . . . . . 269 Foerster. . . . . . . . . . . 270 Foerster. . . . . . . . . . . 271 Forlani. . . . . . . . . . . . . 272 Fotaki. . . . . . . . . . . . . . 025 Friese. . . . . . . . . . . . . . 088 Frøsig. . . . . . . . . . . . . . 026 Furness. . . . . . . . . . . . 273 [ G ] Gabriele. . . . . . . . . . . . 274 Galaine . . . . . . . . . . . . 147 Gary. . . . . . . . . . . . . . . 089 Gaudernack. . . . . . . . 027 Georganaki. . . . . . . . . 275 Gerer. . . . . . . . . . . . . . 028 Gomez-Eerland. . . . 090 Gorris. . . . . . . . . . . . . . 276 Gouttefangeas. . . . . 148 Grees. . . . . . . . . . . . . . 029 Grenov. . . . . . . . . . . . . 030 [ H ] Halldórsdóttir. . . . . . 180 Hammerich. . . . . . . . 031 Harada . . . . . . . . . . . . 032 Hassel. . . . . . . . . . . . . 277 Heidenreich. . . . . . . . 033 Hillerdal. . . . . . . . . . . . 091 Hodgins . . . . . . . . . . . 092 Høgset . . . . . . . . . . . . 034 Holland. . . . . . . . . . . . 225 Holmberg. . . . . . . . . . 035 [ K ] Kapp. . . . . . . . . . . . . . . 227 Kayali. . . . . . . . . . . . . . 228 Kayser. . . . . . . . . . . . . 097 Kedde . . . . . . . . . . . . . 182 Kienzle. . . . . . . . . . . . . 279 Kikodze. . . . . . . . . . . . 229 Kim. . . . . . . . . . . . . . . . 280 Kirkin. . . . . . . . . . . . . . 098 Klaver . . . . . . . . . . . . . 099 Knott. . . . . . . . . . . . . . 281 Koch. . . . . . . . . . . . . . . 282 Koksal. . . . . . . . . . . . . 230 Komdeur. . . . . . . . . . . 283 Konkol. . . . . . . . . . . . . 284 Krächan. . . . . . . . . . . . 183 Kramer . . . . . . . . . . . . 039 Kraus. . . . . . . . . . . . . . 100 Krebs. . . . . . . . . . . . . . 149 Kremer . . . . . . . . . . . . 101 Kreuzberg. . . . . . . . . . 185 Kunert. . . . . . . . . . . . . 102 Kunert. . . . . . . . . . . . . 103 Kuttruff-Coqui . . . . . 040 Kwekkeboom . . . . . . 186 Kwekkeboom . . . . . . 231 Kwekkeboom . . . . . . 232 Kwekkeboom . . . . . . 285 Kyzirakos. . . . . . . . . . 041 [ L ] Lameris. . . . . . . . . . . . 104 Lee. . . . . . . . . . . . . . . . 187 Legscha. . . . . . . . . . . . 105 Lennerz. . . . . . . . . . . . 286 Leon. . . . . . . . . . . . . . . 188 Leon. . . . . . . . . . . . . . . 189 Lichty. . . . . . . . . . . . . . 042 Löffler. . . . . . . . . . . . . 043 Low-Marchelli. . . . . . 287 Lybaert. . . . . . . . . . . . 044 Lyngaa. . . . . . . . . . . . . 150 [ M ] MacLeod. . . . . . . . . . . 106 Mall . . . . . . . . . . . . . . . 107 Mandruzzato. . . . . . . 151 Marcq . . . . . . . . . . . . . 288 Marillier. . . . . . . . . . . . 190 Marschall. . . . . . . . . . 192 Mazorra . . . . . . . . . . . 045 McCreedy. . . . . . . . . . 108 Menevse. . . . . . . . . . . 193 Mensali. . . . . . . . . . . . 109 Metzger . . . . . . . . . . . 289 Michels. . . . . . . . . . . . 194 Mikyšková. . . . . . . . . 046 Miller. . . . . . . . . . . . . . 047 Mitnacht-Kraus. . . . 195 Moise. . . . . . . . . . . . . . 048 Momose. . . . . . . . . . . 290 Montico. . . . . . . . . . . . 049 Mottas . . . . . . . . . . . . 050 Mroz. . . . . . . . . . . . . . . 110 Müller . . . . . . . . . . . . . 051 Mullins . . . . . . . . . . . . 291 [ N ] Nair . . . . . . . . . . . . . . . 052 Nelde. . . . . . . . . . . . . . 053 Nesmiyanov . . . . . . . 292 Niedermann . . . . . . . 152 [ O ] O'Donnell. . . . . . . . . . 233 Oberoi. . . . . . . . . . . . . 111 Okada . . . . . . . . . . . . . 196 Olwill. . . . . . . . . . . . . . 197 Omokoko. . . . . . . . . . 153 Orlinger. . . . . . . . . . . . 054 Owens. . . . . . . . . . . . . 113 Ozdemir. . . . . . . . . . . 293 Özgül Özdemir. . . . . 294 [ P ] Paret. . . . . . . . . . . . . . 198 Park. . . . . . . . . . . . . . . 295 Parri. . . . . . . . . . . . . . . 296 Parrot . . . . . . . . . . . . . 297 Parviainen. . . . . . . . . 234 Peper. . . . . . . . . . . . . . 154 Peres. . . . . . . . . . . . . . 055 Pfeifer. . . . . . . . . . . . . 199 Pfeiffer. . . . . . . . . . . . 114 Platzer. . . . . . . . . . . . . 200 Podola. . . . . . . . . . . . . 056 Podrazil. . . . . . . . . . . . 057 Posselt. . . . . . . . . . . . 201 Prokopi. . . . . . . . . . . . 299 [ Q ] Qureshi. . . . . . . . . . . . 300 Qureshi. . . . . . . . . . . . 301 [ R ] Rabsteyn. . . . . . . . . . 058 Rabu . . . . . . . . . . . . . . 059 Raemdonck. . . . . . . . 115 Ramachandran. . . . . 060 Ramjiawan. . . . . . . . . 302 Rammensee. . . . . . . 061 Ramskov . . . . . . . . . . 202 Rataj . . . . . . . . . . . . . . 117 Rathinasamy. . . . . . . 155 Rekdal. . . . . . . . . . . . . 235 Richards. . . . . . . . . . . 236 Riemer . . . . . . . . . . . . 203 Rodrigues-Santos. . . 156 Röhle. . . . . . . . . . . . . . 303 Rothe. . . . . . . . . . . . . . 063 Ruzicka. . . . . . . . . . . . 204 [ U ] [ S ] Van Acker. . . . . . . . . . 069 Van der Jeught. . . . . 070 van Helden. . . . . . . . . 213 Vascotto. . . . . . . . . . . 324 Verbeke. . . . . . . . . . . . 071 Verdegaal. . . . . . . . . . 325 Vetter . . . . . . . . . . . . . 326 Vigano. . . . . . . . . . . . . 162 Voigt. . . . . . . . . . . . . . . 327 Vormehr. . . . . . . . . . . 072 Voss. . . . . . . . . . . . . . . 133 Saini. . . . . . . . . . . . . . . 304 Sainz. . . . . . . . . . . . . . 064 Sanders. . . . . . . . . . . . 065 Sanders. . . . . . . . . . . . 237 Sandri . . . . . . . . . . . . . 118 Sapega . . . . . . . . . . . . 305 Sapski. . . . . . . . . . . . . 238 Sauer. . . . . . . . . . . . . . 306 Schaft. . . . . . . . . . . . . 119 Schmidt. . . . . . . . . . . . 157 Schmidt. . . . . . . . . . . . 307 Schnieders. . . . . . . . . 205 Schoor. . . . . . . . . . . . . 120 Schörg. . . . . . . . . . . . . 121 Schotte. . . . . . . . . . . . 308 Schrörs. . . . . . . . . . . . 309 Schupp . . . . . . . . . . . . 310 Schuster. . . . . . . . . . . 206 Schütt. . . . . . . . . . . . . 122 Schütz. . . . . . . . . . . . . 066 Schütz. . . . . . . . . . . . . 123 Schwenck. . . . . . . . . . 207 Seo. . . . . . . . . . . . . . . . 311 Seth. . . . . . . . . . . . . . . 067 Shatnyeva. . . . . . . . . 312 Shuttleworth. . . . . . . 208 Simon . . . . . . . . . . . . . 124 Simon . . . . . . . . . . . . . 158 Singh. . . . . . . . . . . . . . 125 Siozopoulou. . . . . . . . 313 Skadborg . . . . . . . . . . 314 Solinas. . . . . . . . . . . . . 315 Solum . . . . . . . . . . . . . 126 Sonner. . . . . . . . . . . . . 316 Spagnuolo. . . . . . . . . 239 Stam . . . . . . . . . . . . . . 159 Steinhoff. . . . . . . . . . . 317 Stoitzner. . . . . . . . . . . 318 Suarez-Carmona. . . 210 Such. . . . . . . . . . . . . . . 128 Urbiola. . . . . . . . . . . . . 068 Uslu. . . . . . . . . . . . . . . 132 [ V ] [ W ] Wälchli. . . . . . . . . . . . . 134 Walter. . . . . . . . . . . . . 214 Weinstein-Marom. . . 135 Welters. . . . . . . . . . . . 163 Welters. . . . . . . . . . . . 164 Wennhold. . . . . . . . . . 136 Westergaard. . . . . . . 137 Wistuba-Hamprecht . 165 Wölfl . . . . . . . . . . . . . . 328 Wollmann. . . . . . . . . . 073 Wulf-Goldenberg. . . 329 [ Y ] Yang. . . . . . . . . . . . . . . 074 [ Z ] Zayoud . . . . . . . . . . . . 330 Zelba. . . . . . . . . . . . . . 215 Zelle-Rieser. . . . . . . . 166 Zhang . . . . . . . . . . . . . 138 Zhao. . . . . . . . . . . . . . . 331 Zhu. . . . . . . . . . . . . . . . 244 [ T ] Taborska. . . . . . . . . . . 129 Tagliamonte. . . . . . . . 240 Tähtinen. . . . . . . . . . . 241 Tanriover. . . . . . . . . . . 319 Taranikanti. . . . . . . . . 320 ten Buren. . . . . . . . . . 321 Theurich. . . . . . . . . . . 242 Thierauf . . . . . . . . . . . 211 Thomé. . . . . . . . . . . . . 322 Tognarelli. . . . . . . . . . 243 Tosi. . . . . . . . . . . . . . . . 130 Treder . . . . . . . . . . . . . 323 Trezise. . . . . . . . . . . . . 212 Tubb. . . . . . . . . . . . . . . 131 Tudor. . . . . . . . . . . . . . 160 Turksma. . . . . . . . . . . 161 65 CRI-CIMT-EATI-AACR SECOND INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE TRANSLATING SCIENCE INTO SURVIVAL September 25-28, 2016 Sheraton New York Times Square Hotel New York, NY Submit an Abstract By: Thursday, June 16, 2016 Register and Save By: Monday, August 8, 2016 CONFERENCE CO-CHAIRPERSONS James P. Allison The University of Texas MD Anderson Cancer Center, Houston, TX Christoph Huber Association for Cancer Immunotherapy (CIMT), Mainz, Germany Philip D. Greenberg Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA Guido Kroemer Institut Gustave Roussy, Villejuif, France ABOUT THIS CONFERENCE The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces to present the International Cancer Immunotherapy Conference. The program will focus on “Translating Science into Survival” and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy. This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates. Continuing Medical Education (CME) Activity–AMA PRA Category 1 CreditsTM available Learn more at CancerImmunotherapyConference.org ANNUAL MEETING MEET AND EAT IN MAINZ Interested in meeting other out-of-town conference participants for dinner? Sign up for a dinner group on May 10 at one of several restaurants in Mainz. For more information, come to the registration desk. Deadline for sign-up is May 10, at 3 p.m.. Imprint POSTAL ADDRESS CIMT - Association for Cancer Immunotherapy Hölderlinstraße 8 55131 Mainz, Germany Telephone: +49 (0) 6131 - 55 47 40 0 Website: www.cimt.eu E-Mail: [email protected] REGISTER OF ASSOCIATIONS Amtsgericht Mainz: VR 3783 CONCEPT AND DESIGN LABOR − Agentur für moderne Kommunikation GmbH Fischtorplatz 21 55116 Mainz, Germany Telephone: +49 (0) 6131 - 30 46 76 2 Website: www.labor.digital PHOTOS Andrea Enderlein © Immunologische Krebs-Therapie e.V. (Association for Cancer Immunotherapy). All rights reserved. We gratefully acknowledge the support from our sponsors. Platinum Gold Silver Bronze Partners Smartphone Schedule Get the CIMT online schedule for your smartphone schedule.cimt.eu Online Abstracts Get the CIMT online abstracts (iPad App, eBook, PDF) abstracts.cimt.eu find us on facebook facebook.com/cimtmainz follow us on twitter twitter.com/C_IMT follow us on Linkedin linkedin.com/company/cimt